Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Abscess
Measurement of alpha-glucosidase activity in serum from patients with cystic fibrosis or pancreatitis.
Acidosis
Rumen microbial and fermentation characteristics are affected differently by acarbose addition during two nutritional types of simulated severe subacute ruminal acidosis in vitro.
Acidosis, Lactic
Oral antidiabetic agents. The emergence of alpha-glucosidase inhibitors.
Acidosis, Lactic
Potential of alpha-glucosidase inhibitors in elderly patients with diabetes mellitus and impaired glucose tolerance.
Acquired Immunodeficiency Syndrome
Prenatal diagnosis of cystic fibrosis by assay of amniotic fluid microvillar enzymes.
Acute Kidney Injury
Acute renal failure related to intravenous immunoglobulin infusion in an elderly woman.
Acute Kidney Injury
[Functional recovery phase of acute renal insufficiency. Behavior and significance of urinary excretion of alpha-glucosidase, gamma-glutamyltransferase, lysozyme and beta 2 microglobulin]
Adenocarcinoma
The cation-independent mannose 6-phosphate receptor is not involved in the polarized secretion of lysosomal alpha-glucosidase from Caco-2 cells.
Adenoma
Neoplasia and hyperplasia of large bowel: focal lesions in an abnormal epithelium.
alpha-galactosidase deficiency
[Clinical, preclinical and prenatal diagnosis of congenital sphingolipidoses by determining lysosomal hydrolases (author's transl)]
alpha-glucosidase deficiency
Abnormal trafficking of sarcolemmal proteins in alpha-glucosidase deficiency.
alpha-glucosidase deficiency
alpha-Glucosidase deficiency (Pompe's disease).
alpha-glucosidase deficiency
Alpha-glucosidase deficiency and basilar artery aneurysm: report of a sibship.
alpha-glucosidase deficiency
Alpha-glucosidase deficiency in a child.
alpha-glucosidase deficiency
alpha-Glucosidase deficiency in generalized glycogenstorage disease (Pompe's disease).
alpha-glucosidase deficiency
Biopsy-proven alpha-glucosidase deficiency with normal lymphocyte enzyme activity.
alpha-glucosidase deficiency
Broad spectrum of Pompe disease in patients with the same c.-32-13T->G haplotype.
alpha-glucosidase deficiency
Canine glycogen storage disease type II. A biochemical study of an acid alpha-glucosidase-deficient Lapland dog.
alpha-glucosidase deficiency
Characterization of intestinal gamma-glucoamylase deficiency in CBA/Ca mice.
alpha-glucosidase deficiency
Clinical Characteristics of Disaccharidase Deficiencies Among Children Undergoing Upper Endoscopy.
alpha-glucosidase deficiency
Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients.
alpha-glucosidase deficiency
Comparative pathology of the canine model of glycogen storage disease type II (Pompe's disease).
alpha-glucosidase deficiency
Cystic fibrosis newborn screening: a model for neuromuscular disease screening?
alpha-glucosidase deficiency
Detection of human acid alpha-glucosidase in fibroblasts using monoclonal antibodies in a biotin-avidin amplified ELISA.
alpha-glucosidase deficiency
Diagnosis of Pompe disease: muscle biopsy vs blood-based assays.
alpha-glucosidase deficiency
Disaccharidase activity in children undergoing esophagogastroduodenoscopy: A systematic review.
alpha-glucosidase deficiency
Effect of enzyme replacement therapy (ERT) added to Home Mechanical Ventilation (HMV) in Adult Pompe disease.
alpha-glucosidase deficiency
Enzyme replacement therapy for infantile Pompe disease during the critical period and identification of a novel mutation.
alpha-glucosidase deficiency
Extended phenotype description and new molecular findings in late onset glycogen storage disease type II: a northern Italy population study and review of the literature.
alpha-glucosidase deficiency
Glycogen storage disease type II in Israel.
alpha-glucosidase deficiency
Improvement of dysphagia in a child affected by Pompe disease treated with enzyme replacement therapy.
alpha-glucosidase deficiency
Late-Onset Glycogen Storage Disease Type II (Pompe's Disease) with a Novel Mutation: A Malaysian Experience.
alpha-glucosidase deficiency
Metabolic Impacts of Maltase Deficiencies.
alpha-glucosidase deficiency
Patients with functional bowel disorder have disaccharidase deficiency: A single-center study from Russia.
alpha-glucosidase deficiency
Prenatal diagnosis of Pompe disease by electron microscopy.
alpha-glucosidase deficiency
Prenatal exclusion of Pompe disease by electron microscopy.
alpha-glucosidase deficiency
Preparation of monoclonal antibodies against acid alpha-D-glucosidase for study of Chinese glycogenosis type II patients.
alpha-glucosidase deficiency
Screening for Pompe disease using a rapid dried blood spot method: experience of a clinical diagnostic laboratory.
alpha-glucosidase deficiency
Selective alteration of brush-border hydrolases in intestinal diseases in childhood.
alpha-glucosidase deficiency
Selective lactase deficiency is common in pediatric patients undergoing upper endoscopy.
alpha-glucosidase deficiency
Selective vacuolar myopathy with atrophy of type II fibers. Occurrence in a childhood case of acid maltase deficiency.
alpha-glucosidase deficiency
Sleep-related obstructive and nonobstructive apneas and neurologic disorders.
alpha-glucosidase deficiency
Small intestinal glucoamylase deficiency and starch malabsorption: a newly recognized alpha-glucosidase deficiency in children.
alpha-glucosidase deficiency
The role of probiotic cultures in the control of gastrointestinal health.
alpha-glucosidase deficiency
Vacuolar myopathy with type 2 A fiber atrophy and type 2 B fiber deficiency. A case of childhood form acid alpha-1,4-glucosidase deficiency.
alpha-glucosidase deficiency
White blood cells and the diagnosis of alpha-glucosidase deficiency.
alpha-glucosidase deficiency
[Disaccharidase deficiency and functional bowel diseases].
alpha-glucosidase deficiency
[Heterogeneity of glycogenosis with alpha-1,4-glucosidase deficiency: enzymatic studies in three families (author's transl)]
alpha-glucosidase deficiency
[Ichthyosiform scaling in alpha-1,4-glucosidase deficiency]
alpha-glucosidase deficiency
[Muscular glycogenosis caused by alpha-1,4-glucosidase deficiency simulating progressive muscular dystrophy. (Clinical and enzyme study. Optic and electron microscopy)]
alpha-glucosidase deficiency
[Pseudodystrophic muscle glycogenosis in adults. (Acid maltase deficiency syndrome) (author's transl)]
Anaphylaxis
Desensitization of an adult patient with Pompe disease and a history of anaphylaxis to alglucosidase alfa.
Aneurysm
Alpha-glucosidase deficiency and basilar artery aneurysm: report of a sibship.
Arthritis
Inhibition of adjuvant arthritis in the rat by phosphosugars and the alpha-glucosidase inhibitor castanospermine.
Arthritis
[Activity of acid hydrolases in rat tissues under experimental arthritis]
Arthritis, Experimental
Alpha-Glucosidase Inhibitors Alter Gut Microbiota and Ameliorate Collagen-Induced Arthritis.
Arthritis, Experimental
Inhibition of adjuvant arthritis in the rat by phosphosugars and the alpha-glucosidase inhibitor castanospermine.
Arthritis, Experimental
[Activity of acid hydrolases in rat tissues under experimental arthritis]
arylsulfatase (type i) deficiency
[Clinical, preclinical and prenatal diagnosis of congenital sphingolipidoses by determining lysosomal hydrolases (author's transl)]
Asthenozoospermia
Epididymal secretory function in men with asthenoteratozoospermia.
Asthenozoospermia
New discriminatory level for glucosidase activity to diagnose epididymal obstruction or dysfunction.
Asthma
Serum neutral alpha-D-glucosidase from patients with cystic fibrosis and chronic pulmonary disease.
Astrocytoma
Activity of glycogen depolymerizing enzymes in extracts from brain tumor tissue (anaplastic astrocytoma and glioblastoma multiforme).
Atherosclerosis
alpha-Glucosidase inhibitor reduces the progression of carotid intima-media thickness.
Atherosclerosis
In vitro inhibitory effects of Limonium contortirameum and L. virgatum extracts from sardinia on alpha-amylase, alpha-glucosidase and pancreatic lipase.
Atherosclerosis
Swings in blood glucose levels accelerate atherogenesis in apolipoprotein E-deficient mice.
Azoospermia
Alpha-1,4-glucosidase activity and the presence of germinal epithelium cells in the semen for differential diagnosis of obstructive and nonobstructive azoospermia.
Azoospermia
Alpha-glucosidase as a specific epididymal enzyme marker. Its validity for the etiologic diagnosis of azoospermia.
Azoospermia
Clinical experience with azoospermia: aetiology and chances for spermatozoa detection upon biopsy.
Azoospermia
Enzymes in the seminal plasma from azoospermic men: correlation with the origin of their azoospermia.
Azoospermia
Improvement in the assessment of human epididymal function by the use of inhibitors in the assay of alpha-glucosidase in seminal plasma.
Azoospermia
Neutral alpha-1,4-glucosidase and fructose levels contribute to discriminating obstructive and nonobstructive azoospermia in Chinese men with azoospermia.
Azoospermia
New discriminatory level for glucosidase activity to diagnose epididymal obstruction or dysfunction.
Azoospermia
Origin of maltase and variations in infertile men.
Azoospermia
Relationship between lipocalin-type prostaglandin D synthase and alpha-glucosidase in azoospermia seminal plasma.
Azoospermia
Relationship between semen quality and the seminal plasma components carnitine, alpha-glucosidase, fructose, citrate and granulocyte elastase in infertile men compared with a normal population.
Azoospermia
Screening for obstruction of the vas deferens in Nigerian men with azoospermia using the alpha-glucosidase reaction in semen.
Azoospermia
Simultaneous measurement of seminal L-carnitine, alpha,1-4-glucosidase, and glycerylphosphorylcholine in azoospermic and oligozoospermic patients.
Azoospermia
[Analysis of the relative etiology of non-obstructive azoospermia]
Azoospermia
[Neutral alpha-glucosidase activity is correlated with the location of epididymal obstruction in azoospermia men].
Azoospermia
[Surgical treatment of obstructive azoospermia: a report of 56 cases]
beta-fructofuranosidase deficiency
Clinical Characteristics of Disaccharidase Deficiencies Among Children Undergoing Upper Endoscopy.
beta-fructofuranosidase deficiency
Disaccharidase activity in children undergoing esophagogastroduodenoscopy: A systematic review.
beta-fructofuranosidase deficiency
Interaction between dietary carbohydrates and intestinal disaccharidases in experimental diarrhea.
beta-fructofuranosidase deficiency
Patients with functional bowel disorder have disaccharidase deficiency: A single-center study from Russia.
beta-glucosidase deficiency
[Clinical, preclinical and prenatal diagnosis of congenital sphingolipidoses by determining lysosomal hydrolases (author's transl)]
Breast Neoplasms
Differential proteome analysis of replicative senescence in rat embryo fibroblasts.
Breast Neoplasms
Serum beta-N-acetylglucosaminidase, beta-D-glucosidase, alpha-D-glucosidase, beta-D-fucosidase, alpha-L-fucosidase and beta-D-galactosidase levels in acute viral hepatitis, pancreatitis, myocardial infarction and breast cancer.
Carcinoma
Neoplasia and hyperplasia of large bowel: focal lesions in an abnormal epithelium.
Carcinoma
New antihyperglycemic, alpha-glucosidase inhibitory, and cytotoxic derivatives of benzimidazoles.
Carcinoma, Hepatocellular
Alpha-glucosidase activity in reference to glycogen storage, and formation of glycogenosomes in ascites hepatoma AH13 cells. Comparison of AH13 cells with ascites hepatoma AH109A and normal liver.
Carcinoma, Hepatocellular
Antiviral effect of {alpha}-glucosidase inhibitors on viral morphogenesis and binding properties of hepatitis C virus-like particles.
Carcinoma, Hepatocellular
Biochemical microanalysis of alpha-glucosidase activity in preneoplastic and neoplastic hepatic lesions induced in rats by N-nitrosomorpholine.
Carcinoma, Hepatocellular
Serum and host liver activities of glycosidases and sialyltransferases in animals bearing transplantable tumors.
Carcinoma, Hepatocellular
Thiazolidinediones, alpha-glucosidase inhibitors, meglitinides, sulfonylureas, and hepatocellular carcinoma risk: A meta-analysis.
Cardiomegaly
Long-term follow-up results in enzyme replacement therapy for Pompe disease: a case report.
Cardiomyopathies
A review of treatment of Pompe disease in infants.
Cardiomyopathies
Antisense Oligonucleotide-mediated Suppression of Muscle Glycogen Synthase 1 Synthesis as an Approach for Substrate Reduction Therapy of Pompe Disease.
Cardiomyopathies
Cardiac responses in paediatric Pompe disease in the ADVANCE patient cohort.
Cardiomyopathies
Enhanced response to enzyme replacement therapy in pompe disease after the induction of immune tolerance.
Cardiomyopathies
Enzyme replacement therapy for infantile-onset Pompe disease.
Cardiomyopathies
Fractures in children with Pompe disease: a potential long-term complication.
Cardiomyopathies
Glycogen storage disease types I and II: treatment updates.
Cardiomyopathies
High dose IVIG successfully reduces high rhGAA IgG antibody titers in a CRIM-negative infantile Pompe disease patient.
Cardiomyopathies
Long-term enzyme replacement therapy for pompe disease with recombinant human alpha-glucosidase derived from chinese hamster ovary cells.
Cardiomyopathies
New therapeutic approaches for Pompe disease: enzyme replacement therapy and beyond.
Cardiomyopathies
Postmortem Findings and Clinical Correlates in Individuals with Infantile-Onset Pompe Disease.
Cardiomyopathies
Recombinant human alpha-glucosidase from rabbit milk in Pompe patients.
Cardiomyopathies
[Cardiomuscular lysosomal glycogenosis in adults without known enzyme deficiency. A cause of familial myocardiopathy and lysosomal glycogen overload with normal acid maltase]
Cardiovascular Diseases
Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.
Cardiovascular Diseases
Acarbose, an alpha-glucosidase inhibitor, decreases aortic gene expression and serum levels of monocyte chemoattractant protein-1 in fructose-fed rats.
Cardiovascular Diseases
Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose.
Cardiovascular Diseases
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2016 EXECUTIVE SUMMARY.
Cardiovascular Diseases
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY.
Cardiovascular Diseases
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY.
Cardiovascular Diseases
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY.
Cardiovascular Diseases
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2020 EXECUTIVE SUMMARY.
Cardiovascular Diseases
Inhibitory effects of estrogens on digestive enzymes, insulin deficiency, and pancreas toxicity in diabetic rats.
Cardiovascular Diseases
Miglitol improves postprandial endothelial dysfunction in patients with acute coronary syndrome and new-onset postprandial hyperglycemia.
Cardiovascular Diseases
Single administration of alpha-glucosidase inhibitors on endothelial function and incretin secretion in diabetic patients with coronary artery disease - Juntendo University trial: effects of miglitol on endothelial vascular reactivity in type 2 diabetic patients with coronary heart disease (J-MACH) -.
Cardiovascular Diseases
Systemic medications and cortical cataract: the Singapore Epidemiology of Eye Diseases Study.
Cardiovascular Diseases
[The clinical significance of early intervention for impaired glucose tolerance]
Cataract
Systemic medications and cortical cataract: the Singapore Epidemiology of Eye Diseases Study.
Celiac Disease
Review: Management of postprandial diarrhea syndrome.
Celiac Disease
[Carbohydrase activities may serve as a marker for small intestinal mucosal recovery in patients with celiac disease].
Cholestasis
Influence of biliary stasis on the activity and distribution of maltase, sucrase, alkaline phosphatase, and leucylnaphthylamidase in the small intestine of the mouse.
Cholestasis, Extrahepatic
Activity of alpha-1,4-glucosidase in extrahepatic cholestasis and acute viral hepatitis.
Cholestasis, Intrahepatic
[The influences of endogenous bile acids on maltase and alkaline phosphatase activities in intrahepatic cholestasis rats]
Colonic Neoplasms
Effects of acetaldehyde on brush border enzyme activities in human colon adenocarcinoma cell line Caco-2.
Colonic Neoplasms
Lysosomal alpha-glucosidase: cell-specific processing and altered maturation in HT-29 colon cancer cells.
Communicable Diseases
Mineral Analysis, In Vitro Evaluation of Alpha-Amylase, Alpha-Glucosidase, and Beta-Galactosidase Inhibition, and Antibacterial Activities of Juglans regia L. Bark Extracts.
Coronary Artery Disease
Single administration of alpha-glucosidase inhibitors on endothelial function and incretin secretion in diabetic patients with coronary artery disease - Juntendo University trial: effects of miglitol on endothelial vascular reactivity in type 2 diabetic patients with coronary heart disease (J-MACH) -.
Coronary Disease
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2016 EXECUTIVE SUMMARY.
Coronary Disease
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY.
Coronary Disease
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY.
Coronary Disease
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY.
Coronary Disease
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2020 EXECUTIVE SUMMARY.
Coronary Disease
Single administration of alpha-glucosidase inhibitors on endothelial function and incretin secretion in diabetic patients with coronary artery disease - Juntendo University trial: effects of miglitol on endothelial vascular reactivity in type 2 diabetic patients with coronary heart disease (J-MACH) -.
Cystic Fibrosis
Acid hydrolases in sera and plasma from patients with cystic fibrosis.
Cystic Fibrosis
Activity levels and properties of acid alpha-glucosidase from liver and neutral alpha-glucosidase from sera of cystic fibrosis patients and controls.
Cystic Fibrosis
Alpha-glucosidase in cystic fibrosis.
Cystic Fibrosis
Characteristics of maltase activity in amniotic fluid.
Cystic Fibrosis
Disaccharidase deficiency in amniotic fluid from cases of cystic fibrosis.
Cystic Fibrosis
Enzyme analysis of amniotic fluid for prenatal diagnosis of cystic fibrosis in high-risk pregnancies.
Cystic Fibrosis
Glycosidases in serum of cystic fibrosis patients.
Cystic Fibrosis
Measurement of alpha-glucosidase activity in serum from patients with cystic fibrosis or pancreatitis.
Cystic Fibrosis
Prenatal detection of cystic fibrosis; comparative study of maltase and alkaline phosphatase activities in amniotic fluid.
Cystic Fibrosis
Prenatal diagnosis of cystic fibrosis by assay of amniotic fluid microvillar enzymes.
Cystic Fibrosis
Rescue of functional delF508-CFTR channels in cystic fibrosis epithelial cells by the alpha-glucosidase inhibitor miglustat.
Cystic Fibrosis
Seminal plasma characteristics as indicators of cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in men with obstructive azoospermia.
Cystic Fibrosis
Serum neutral alpha-D-glucosidase from patients with cystic fibrosis and chronic pulmonary disease.
Cystic Fibrosis
Small intestinal brush border enzymes in cystic fibrosis.
Cystic Fibrosis
Studies in meconium: disaccharidase activities in meconium from cystic fibrosis patients and controls.
Cysts
Intestinal alpha-glucosidase inhibitors: abdominal gas cysts.
Deglutition Disorders
Improvement of dysphagia in a child affected by Pompe disease treated with enzyme replacement therapy.
Dementia
Loss of endoplasmic reticulum-associated enzymes in affected brain regions in Huntington's disease and Alzheimer-type dementia.
Dengue
Alpha-glucosidase inhibitors reduce dengue virus production by affecting the initial steps of virion morphogenesis in the endoplasmic reticulum.
Dengue
Castanospermine, a potent inhibitor of dengue virus infection in vitro and in vivo.
Dental Caries
Partial purification and characterization of alpha-glucosidase from Rothia dentocariosa.
Dental Plaque
Effect of the alpha-glucosidase inhibitor, acarbose, on disaccharide splitting enzymes in human dental plaque.
Dental Plaque
Sucrase and maltase activities in supragingival dental plaque in humans of streptococcal, actinomyces and lactobacilli species.
Dermatomyositis
Additive contribution of multiple factors in the development of pneumatosis intestinalis: a case report and review of the literature.
Diabetes Complications
Combination of oral antidiabetic drugs and insulin in the treatment of non-insulin-dependent diabetes.
Diabetes Complications
Repetitive postprandial hyperglycemia increases cardiac ischemia/reperfusion injury: prevention by the alpha-glucosidase inhibitor acarbose.
Diabetes Complications
The mechanism of alpha-glucosidase inhibition in the management of diabetes.
Diabetes Complications
[Development of alpha-glucosidase inhibitor from medicinal herbs]
Diabetes Mellitus
A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease.
Diabetes Mellitus
A series of cinnamic acid derivatives and their inhibitory activity on intestinal alpha-glucosidase.
Diabetes Mellitus
Acarbose related diarrhea: increased butyrate upregulates prostaglandin E.
Diabetes Mellitus
Acarbose: its role in the treatment of diabetes mellitus.
Diabetes Mellitus
Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients.
Diabetes Mellitus
alpha-Glucosidase and alpha-amylase inhibitory activities of saponins from traditional Chinese medicines in the treatment of diabetes mellitus.
Diabetes Mellitus
alpha-Glucosidase inhibition in the treatment of diabetes mellitus.
Diabetes Mellitus
Alpha-glucosidase inhibitor use is associated with decreased colorectal neoplasia risk in patients with type 2 diabetes mellitus receiving colonoscopy: a retrospective study.
Diabetes Mellitus
Alpha-glucosidase inhibitors and risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis.
Diabetes Mellitus
Alpha-glucosidase inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus.
Diabetes Mellitus
Alpha-glucosidase inhibitors for type 2 diabetes mellitus.
Diabetes Mellitus
Alpha-glucosidase inhibitory activity and lipid-lowering mechanisms of Moringa oleifera leaf extract.
Diabetes Mellitus
Amelioration of Diabetes mellitus by modulation of GLP-1 via targeting alpha-glucosidase using Acacia tortilis polysaccharide in Streptozotocin-Nicotinamide induced diabetes in rats.
Diabetes Mellitus
An ?-glucosidase inhibitor could reduce T-wave alternans in type 2 diabetes patients.
Diabetes Mellitus
An evaluation of the potential side-effects of alpha-glucosidase inhibitors used for the management of diabetes mellitus.
Diabetes Mellitus
Association between ?-glucosidase inhibitor use and psoriatic disease risk in patients with type 2 diabetes mellitus: A population-based cohort study.
Diabetes Mellitus
Changes in alpha-glucosidase activities along the jejunal-ileal axis of normal rats by the alpha-glucosidase inhibitor miglitol.
Diabetes Mellitus
Clinical effect of combination therapy of pioglitazone and an alpha-glucosidase inhibitor.
Diabetes Mellitus
Clinical inquiries. What is the best medical therapy for new-onset type 2 diabetes?
Diabetes Mellitus
Comparative RNA-sequencing of the acarbose producer Actinoplanes sp. SE50/110 cultivated in different growth media.
Diabetes Mellitus
Comparison of the effect of glucose-lowering agents on the risk of atrial fibrillation: A network meta-analysis.
Diabetes Mellitus
Complete genome sequence of the actinobacterium Streptomyces glaucescens GLA.O (DSM 40922) consisting of a linear chromosome and one linear plasmid.
Diabetes Mellitus
Diabetes mellitus secondary to glycogen storage disease type III.
Diabetes Mellitus
Do Alpha-glucosidase Inhibitors Have the Potential to Induce Portal Venous Gas? -Two Clinical Case Reports.
Diabetes Mellitus
Dose-dependent efficacy of miglitol, an alpha-glucosidase inhibitor, in type 2 diabetic patients on diet alone: results of a 24-week double-blind placebo-controlled study.
Diabetes Mellitus
Effect of a new hypoglycemic agent, A-4166 [(-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine], on postprandial blood glucose excursion: comparison with voglibose and glibenclamide.
Diabetes Mellitus
Effect of acarbose on postprandial lipid metabolism in type 2 diabetes mellitus.
Diabetes Mellitus
Effect of acarbose, an alpha-glucosidase inhibitor, on serum lipoprotein lipase mass levels and common carotid artery intima-media thickness in type 2 diabetes mellitus treated by sulfonylurea.
Diabetes Mellitus
Effect of an alpha-glucosidase inhibitor (BAY m 1099) on post-prandial blood glucose and insulin in type II diabetics.
Diabetes Mellitus
Effect of Ca(2+) on the activity and structure of ?-glucosidase: Inhibition kinetics and molecular dynamics simulations.
Diabetes Mellitus
Effect of inhibition of alpha-glucosidase on age-related glucose intolerance and pancreatic atrophy in rats.
Diabetes Mellitus
Effect of pioglitazone on muscle sympathetic nerve activity in type 2 diabetes mellitus with alpha-glucosidase inhibitor.
Diabetes Mellitus
Effect of the alpha-glucosidase inhibitor acarbose on control of glycemia in dogs with naturally acquired diabetes mellitus.
Diabetes Mellitus
Effects of 8-wk alpha-glucosidase inhibition on metabolic control, C-peptide secretion, hepatic glucose output, and peripheral insulin sensitivity in poorly controlled type II diabetic patients.
Diabetes Mellitus
Effects of alpha-glucosidase inhibition on meal glucose tolerance and timing of insulin administration in patients with type I diabetes mellitus.
Diabetes Mellitus
Effects of beano on the tolerability and pharmacodynamics of acarbose.
Diabetes Mellitus
Effects of changeover from voglibose to acarbose on postprandial triglycerides in type 2 diabetes mellitus patients.
Diabetes Mellitus
Effects of diabetes and hyperglycemia on disaccharidase activities in the rat.
Diabetes Mellitus
Effects of L-malic Acid on alpha-glucosidase: inhibition kinetics and computational molecular dynamics simulations.
Diabetes Mellitus
Efficacy of combined use of miglitol in Type 2 diabetes patients receiving insulin therapy-placebo-controlled double-blind comparative study.
Diabetes Mellitus
Established therapies for diabetes mellitus.
Diabetes Mellitus
Hypoglycemic and hypolipidemic effects of Saururus chinensis Baill in streptozotocin-induced diabetic rats.
Diabetes Mellitus
Improving management of type 2 diabetes mellitus: 1. alpha-Glucosidase inhibitors.
Diabetes Mellitus
Improving the genome annotation of the acarbose producer Actinoplanes sp. SE50/110 by sequencing enriched 5'-ends of primary transcripts.
Diabetes Mellitus
In vitro alpha-glucosidase and alpha-amylase enzyme inhibitory effects of Andrographis paniculata extract and andrographolide.
Diabetes Mellitus
Inhibition of alpha-glucosidase and amylase by luteolin, a flavonoid.
Diabetes Mellitus
Inhibitory activity of Euonymus alatus against alpha-glucosidase in vitro and in vivo.
Diabetes Mellitus
Inhibitory effect of Azadirachta indica A. juss leaf extract on the activities of alpha-amylase and alpha-glucosidase.
Diabetes Mellitus
Inhibitory effect of phloroglucinol on ?-glucosidase: Kinetics and molecular dynamics simulation integration study.
Diabetes Mellitus
Isolation and characterization of an iridoid, Arbortristoside-C from Nyctanthes arbor-tristis Linn., a potential drug candidate for diabetes targeting ?-glucosidase.
Diabetes Mellitus
Long-term effectiveness of a new alpha-glucosidase inhibitor (BAY m1099-miglitol) in insulin-treated type 2 diabetes mellitus.
Diabetes Mellitus
Long-term ingestion of a fermented soybean-derived Touchi-extract with alpha-glucosidase inhibitory activity is safe and effective in humans with borderline and mild type-2 diabetes.
Diabetes Mellitus
Long-term treatment with acarbose for the treatment of reactive hypoglycemia.
Diabetes Mellitus
Neuroprotective effects of Moringa oleifera: Bio-guided GC-MS identification of active compounds in diabetic neuropathic pain model.
Diabetes Mellitus
Oral hypoglycemic agents: insulin secretagogues, alpha-glucosidase inhibitors and insulin sensitizers.
Diabetes Mellitus
Pharmacologic management of the older patient with type 2 diabetes mellitus.
Diabetes Mellitus
Pioglitazone produces rapid and persistent reduction of vascular inflammation in patients with hypertension and type 2 diabetes mellitus who are receiving angiotensin II receptor blockers.
Diabetes Mellitus
Pneumatosis cystoides intestinalis after alpha-glucosidase inhibitor treatment in a patient with interstitial pneumonitis.
Diabetes Mellitus
Pneumatosis cystoides intestinalis in neuropsychiatric systemic lupus erythematosus with diabetes mellitus: case report and literature review.
Diabetes Mellitus
Pneumatosis cystoides intestinalis of the ascending colon related to acarbose treatment: a case report.
Diabetes Mellitus
Potent alpha-glucosidase inhibitors purified from the red alga Grateloupia elliptica.
Diabetes Mellitus
Potential of alpha-glucosidase inhibitors in elderly patients with diabetes mellitus and impaired glucose tolerance.
Diabetes Mellitus
Safe and effective treatment of diabetes mellitus associated with chronic liver diseases with an alpha-glucosidase inhibitor, acarbose.
Diabetes Mellitus
Structural and functional characterization of polyphenols isolated from acerola (Malpighia emarginata DC.) fruit.
Diabetes Mellitus
Synergisms in Alpha-glucosidase Inhibition and Antioxidant Activity of Camellia sinensis L. Kuntze and Eugenia uniflora L. Ethanolic Extracts.
Diabetes Mellitus
Synthesis of novel triterpene and N-allylated/N-alkylated niacin hybrids as ?-glucosidase inhibitors.
Diabetes Mellitus
Synthesis, biological activity, and molecular modeling studies of 1H-1,2,3-triazole derivatives of carbohydrates as alpha-glucosidases inhibitors.
Diabetes Mellitus
Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus.
Diabetes Mellitus
The alpha-glucosidase inhibitor miglitol decreases glucose fluctuations and inflammatory cytokine gene expression in peripheral leukocytes of Japanese patients with type 2 diabetes mellitus.
Diabetes Mellitus
The complete genome sequence of the acarbose producer Actinoplanes sp. SE50/110.
Diabetes Mellitus
The effect of two new alpha-glucosidase inhibitors on metabolic responses to a mixed meal in normal volunteers.
Diabetes Mellitus
The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus.
Diabetes Mellitus
Treatment of feline diabetes mellitus using an alpha-glucosidase inhibitor and a low-carbohydrate diet.
Diabetes Mellitus
Treatment of type 2 diabetes mellitus in children and adolescents.
Diabetes Mellitus
Type 2 diabetes mellitus: what is the optimal treatment regimen?
Diabetes Mellitus
Urinary excretion of beta-glucuronidase, N-acetyl-beta-D-glucosaminidase, alpha-glucosidase and trehalase in diabetes mellitus.
Diabetes Mellitus
[Alpha-glucosidase inhibitor for the prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese subjects with impaired glucose tolerance]
Diabetes Mellitus
[alpha-Glucosidase inhibitors in the therapy of diabetes mellitus]
Diabetes Mellitus
[Alpha-glucosidase inhibitors: a new therapeutic approach in diabetes and functional hypoglycemia]
Diabetes Mellitus
[Current status of the treatment of type 2 diabetes mellitus. Alpha-glucosidase inhibitors]
Diabetes Mellitus
[Drug clinics. How I treat various metabolic diseases treated by a drug intervention that targets the intestine]
Diabetes Mellitus
[Study on the inhibition of alpha-glucosidase by soyasaponins]
Diabetes Mellitus
[The alpha-glucosidase inhibitor miglitol for the treatment of type 2 diabetes mellitus in the doctor's office]
Diabetes Mellitus
[The use of the alpha-glucosidase inhibitor acarbose for the treatment of type-2 diabetes mellitus in secondary sulfanilamide resistance]
Diabetes Mellitus
[Treatment of type 2 diabetes mellitus with the alpha-glucosidase inhibitor Miglitol in the doctor's office]
Diabetes Mellitus
[Use of oral hypoglycemic agents in patients with chronic kidney failure.]
Diabetes Mellitus, Type 1
A new alpha-glucosidase inhibitor (Bay-m-1099) reduces insulin requirements with meals in insulin-dependent diabetes mellitus.
Diabetes Mellitus, Type 1
Alpha-glucosidase inhibition and timing of preprandial insulin in patients with insulin-dependent diabetes mellitus (IDDM).
Diabetes Mellitus, Type 1
Alpha-glucosidase inhibition as an adjunct to the treatment of type 1 diabetes.
Diabetes Mellitus, Type 1
alpha-Glucosidase inhibition improves postprandial hyperglycemia and decreases insulin requirements in insulin-dependent diabetes mellitus.
Diabetes Mellitus, Type 1
Alternative Agents in Type 1 Diabetes in Addition to Insulin Therapy: Metformin, Alpha-Glucosidase Inhibitors, Pioglitazone, GLP-1 Agonists, DPP-IV Inhibitors, and SGLT-2 Inhibitors.
Diabetes Mellitus, Type 1
Discovery of novel pyrido-pyrrolidine hybrid compounds as alpha-glucosidase inhibitors and alternative agent for control of type 1 diabetes.
Diabetes Mellitus, Type 1
Effects of prolonged (6 months) alpha-glucosidase inhibition on blood glucose control and insulin requirements in patients with insulin-dependent diabetes mellitus.
Diabetes Mellitus, Type 1
Effects of prolonged administration of two new alpha-glucosidase inhibitors on blood glucose control, insulin requirements and breath hydrogen excretion in patients with insulin-dependent diabetes mellitus.
Diabetes Mellitus, Type 1
Effects of two new alpha-glucosidase inhibitors on glycemic control in patients with insulin-dependent diabetes mellitus.
Diabetes Mellitus, Type 1
Nocturnal hypoglycemia in type 1 diabetes: an assessment of preventive bedtime treatments.
Diabetes Mellitus, Type 1
Oral hypoglycemic agents: insulin secretagogues, alpha-glucosidase inhibitors and insulin sensitizers.
Diabetes Mellitus, Type 1
[Valibose, an alpha-glucosidase inhibitor, ameliorates the metabolic disorder of glucose and lipids and the nephropathy in streptozotocin-induced diabetic rats].
Diabetes Mellitus, Type 2
A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease.
Diabetes Mellitus, Type 2
A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44)
Diabetes Mellitus, Type 2
A randomized, double-blind, placebo-controlled trial to assess safety and tolerability during treatment of type 2 diabetes with usual diabetes therapy and either Cycloset or placebo.
Diabetes Mellitus, Type 2
A TLC bioautographic method for the detection of alpha- and beta-glucosidase inhibitors in plant extracts.
Diabetes Mellitus, Type 2
Acarbose attenuates experimental non-alcoholic steatohepatitis.
Diabetes Mellitus, Type 2
Acarbose for the treatment of type II diabetes: the results of a Canadian multi-centre trial.
Diabetes Mellitus, Type 2
Acarbose improves glycemic control and reduces body weight: Subanalysis data of South Asia region.
Diabetes Mellitus, Type 2
Acarbose in the treatment of elderly patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Acarbose is a promising therapeutic strategy for the treatment of patients with nonalcoholic steatohepatitis (NASH).
Diabetes Mellitus, Type 2
Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance.
Diabetes Mellitus, Type 2
Acarbose treatment of non-insulin-dependent diabetes mellitus.
Diabetes Mellitus, Type 2
Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients.
Diabetes Mellitus, Type 2
Alpha glucosidase inhibition in the treatment of non-insulin-dependent diabetes mellitus.
Diabetes Mellitus, Type 2
alpha-Glucosidase inhibition by miglitol in NIDDM patients.
Diabetes Mellitus, Type 2
alpha-Glucosidase inhibitor reduces the progression of carotid intima-media thickness.
Diabetes Mellitus, Type 2
Alpha-glucosidase inhibitor use is associated with decreased colorectal neoplasia risk in patients with type 2 diabetes mellitus receiving colonoscopy: a retrospective study.
Diabetes Mellitus, Type 2
Alpha-glucosidase inhibitor, acarbose, improves glycamic control and reduces body weight in type 2 diabetes: Findings on indian patients from the pooled data analysis.
Diabetes Mellitus, Type 2
Alpha-glucosidase inhibitors and hepatotoxicity in type 2 diabetes: a systematic review and meta-analysis.
Diabetes Mellitus, Type 2
Alpha-glucosidase inhibitors for patients with type 2 diabetes: response to van de Laar et al.
Diabetes Mellitus, Type 2
Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis.
Diabetes Mellitus, Type 2
Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose.
Diabetes Mellitus, Type 2
Alpha-glucosidase inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Alpha-glucosidase inhibitors for type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
alpha-Glucosidase inhibitors in diabetes: efficacy in NIDDM subjects.
Diabetes Mellitus, Type 2
alpha-Glucosidase inhibitors in diabetes: lessons from animal studies.
Diabetes Mellitus, Type 2
Alpha-glucosidase inhibitors in the early treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
Alpha-glucosidase inhibitors may reduce the risk of type 2 diabetes.
Diabetes Mellitus, Type 2
An ?-glucosidase inhibitor could reduce T-wave alternans in type 2 diabetes patients.
Diabetes Mellitus, Type 2
An alpha-glucosidase inhibitor, acarbose treatment decreases serum levels of glyceraldehyde-derived advanced glycation end products (AGEs) in patients with type 2 diabetes.
Diabetes Mellitus, Type 2
An importance of carbohydrate ingestion for the expression of the effect of alpha-glucosidase inhibitor in NIDDM.
Diabetes Mellitus, Type 2
Association between ?-glucosidase inhibitor use and psoriatic disease risk in patients with type 2 diabetes mellitus: A population-based cohort study.
Diabetes Mellitus, Type 2
Beneficial effect of long-term combined treatment with voglibose and pioglitazone on pancreatic islet function of genetically diabetic GK rats.
Diabetes Mellitus, Type 2
Beneficial effects of vildagliptin combined with miglitol on glucose tolerance and islet morphology in diet-controlled db/db mice.
Diabetes Mellitus, Type 2
Blood glucose-lowering activity of colestimide in patients with type 2 diabetes and hypercholesterolemia: a case-control study comparing colestimide with acarbose.
Diabetes Mellitus, Type 2
Can alpha-glucosidase inhibitors reduce the dosage of sulphonylurea compounds needed by patients with non-insulin-dependent diabetes mellitus?
Diabetes Mellitus, Type 2
Can alpha-glucosidase inhibitors reduce the insulin dosage administered to patients with non-insulin-dependent diabetes mellitus?
Diabetes Mellitus, Type 2
Changes in alpha-glucosidase activities along the jejunal-ileal axis of normal rats by the alpha-glucosidase inhibitor miglitol.
Diabetes Mellitus, Type 2
Characteristics of Food Protein-Derived Antidiabetic Bioactive Peptides: A Literature Update.
Diabetes Mellitus, Type 2
Chronic treatment of African-American type 2 diabetic patients with alpha-glucosidase inhibition.
Diabetes Mellitus, Type 2
Clinical effect of combination therapy of pioglitazone and an alpha-glucosidase inhibitor.
Diabetes Mellitus, Type 2
Clinical evaluation of pioglitazone in patients with type 2 diabetes using alpha-glucosidase inhibitor and examination of its efficacy profile.
Diabetes Mellitus, Type 2
Combination of oral antidiabetic drugs and insulin in the treatment of non-insulin-dependent diabetes.
Diabetes Mellitus, Type 2
Combination therapy of alpha-glucosidase inhibitor and a sulfonylurea compound prolongs the duration of good glycemic control.
Diabetes Mellitus, Type 2
Comparative safety of newer oral antidiabetic drugs.
Diabetes Mellitus, Type 2
Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes: results of the 3D trial.
Diabetes Mellitus, Type 2
Comparison of Lipid-Lowering Effects of Anagliptin and Miglitol in Patients With Type 2 Diabetes: A Randomized Trial.
Diabetes Mellitus, Type 2
Comparison of the effect of glucose-lowering agents on the risk of atrial fibrillation: A network meta-analysis.
Diabetes Mellitus, Type 2
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2016 EXECUTIVE SUMMARY.
Diabetes Mellitus, Type 2
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY.
Diabetes Mellitus, Type 2
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY.
Diabetes Mellitus, Type 2
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY.
Diabetes Mellitus, Type 2
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2020 EXECUTIVE SUMMARY.
Diabetes Mellitus, Type 2
Considerations when using alpha-glucosidase inhibitors in the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
Correlations of fasting and postprandial blood glucose increments to the overall diurnal hyperglycemic status in type 2 diabetic patients: variations with levels of HbA1c.
Diabetes Mellitus, Type 2
Dose-dependent efficacy of miglitol, an alpha-glucosidase inhibitor, in type 2 diabetic patients on diet alone: results of a 24-week double-blind placebo-controlled study.
Diabetes Mellitus, Type 2
Dose-response profile of acarbose in older subjects with type 2 diabetes.
Diabetes Mellitus, Type 2
DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study.
Diabetes Mellitus, Type 2
Effect of acarbose (alpha-glucosidase inhibitor) on disaccharase activity in small intestine in KK-Ay and ddY mice.
Diabetes Mellitus, Type 2
Effect of acarbose (BAY-g-5421) on expression of noninsulin-dependent diabetes mellitus in sucrose-fed SHR/N-corpulent rats.
Diabetes Mellitus, Type 2
Effect of acarbose on glucose intolerance in patients with non-insulin-dependent diabetes mellitus.
Diabetes Mellitus, Type 2
Effect of acarbose on insulin sensitivity in elderly patients with diabetes.
Diabetes Mellitus, Type 2
Effect of acarbose on postprandial lipid metabolism in type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Effect of acarbose, an alpha-glucosidase inhibitor, on serum lipoprotein lipase mass levels and common carotid artery intima-media thickness in type 2 diabetes mellitus treated by sulfonylurea.
Diabetes Mellitus, Type 2
Effect of alpha-glucosidase inhibitor in combination with sulphonylurea compounds on lipid profile in patients with non-insulin-dependent diabetes mellitus.
Diabetes Mellitus, Type 2
Effect of an alpha-glucosidase inhibitor (voglibose), in combination with sulphonylureas, on glycaemic control in type 2 diabetes patients.
Diabetes Mellitus, Type 2
Effect of an alpha-glucosidase inhibitor combined with sulphonylurea treatment on glucose metabolism in patients with non-insulin-dependent diabetes mellitus.
Diabetes Mellitus, Type 2
Effect of an alpha-glucosidase inhibitor on intestinal fermentation and faecal lipids in diabetic patients.
Diabetes Mellitus, Type 2
Effect of Ca(2+) on the activity and structure of ?-glucosidase: Inhibition kinetics and molecular dynamics simulations.
Diabetes Mellitus, Type 2
Effect of pioglitazone on muscle sympathetic nerve activity in type 2 diabetes mellitus with alpha-glucosidase inhibitor.
Diabetes Mellitus, Type 2
Effect of race on the glycaemic response to sitagliptin: Insights from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
Diabetes Mellitus, Type 2
Effects of alpha-glucosidase inhibitor (acarbose) combined with sulfonylurea or sulfonylurea and metformin in treatment of non-insulin-dependent diabetes mellitus.
Diabetes Mellitus, Type 2
Effects of BAYm 1099, new alpha-glucosidase inhibitor, on acute metabolic responses and metabolic control in NIDDM over 1 mo.
Diabetes Mellitus, Type 2
Effects of beano on the tolerability and pharmacodynamics of acarbose.
Diabetes Mellitus, Type 2
Effects of changeover from voglibose to acarbose on postprandial triglycerides in type 2 diabetes mellitus patients.
Diabetes Mellitus, Type 2
Effects of current therapeutic interventions on insulin resistance.
Diabetes Mellitus, Type 2
Effects of L-malic Acid on alpha-glucosidase: inhibition kinetics and computational molecular dynamics simulations.
Diabetes Mellitus, Type 2
Effects of long-term treatment with alpha-glucosidase inhibitor on the peripheral nerve function and structure in Goto-Kakizaki rats: a genetic model for type 2 diabetes.
Diabetes Mellitus, Type 2
Effects of voglibose on glycemic excursions, insulin secretion, and insulin sensitivity in non-insulin-treated NIDDM patients.
Diabetes Mellitus, Type 2
Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial.
Diabetes Mellitus, Type 2
Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen Study.
Diabetes Mellitus, Type 2
Efficacy of alpha-glucosidase inhibitors on lipids in NIDDM subjects with moderate hyperlipidaemia.
Diabetes Mellitus, Type 2
Efficacy of combined use of miglitol in Type 2 diabetes patients receiving insulin therapy-placebo-controlled double-blind comparative study.
Diabetes Mellitus, Type 2
Emerging strategies for the activity assay and inhibitor screening of alpha-glucosidase.
Diabetes Mellitus, Type 2
Evaluation of antihyperglycemia and antihypertension potential of native Peruvian fruits using in vitro models.
Diabetes Mellitus, Type 2
Evaluation of indigenous grains from the Peruvian Andean region for antidiabetes and antihypertension potential using in vitro methods.
Diabetes Mellitus, Type 2
Glitazones and alpha-glucosidase inhibitors as the second-line oral anti-diabetic agents added to metformin reduce cardiovascular risk in Type 2 diabetes patients: a nationwide cohort observational study.
Diabetes Mellitus, Type 2
Improving management of type 2 diabetes mellitus: 1. alpha-Glucosidase inhibitors.
Diabetes Mellitus, Type 2
In vitro alpha-glucosidase and alpha-amylase enzyme inhibitory effects of Andrographis paniculata extract and andrographolide.
Diabetes Mellitus, Type 2
In vitro potential of Ascophyllum nodosum phenolic antioxidant-mediated alpha-glucosidase and alpha-amylase inhibition.
Diabetes Mellitus, Type 2
Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting.
Diabetes Mellitus, Type 2
Inhibition of alpha-glucosidase by aqueous extracts of some potent antidiabetic medicinal herbs.
Diabetes Mellitus, Type 2
Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
Diabetes Mellitus, Type 2
Inhibitory effect of koji Aspergillus terreus on alpha-glucosidase activity and postprandial hyperglycemia.
Diabetes Mellitus, Type 2
Inhibitory effect of phloroglucinol on ?-glucosidase: Kinetics and molecular dynamics simulation integration study.
Diabetes Mellitus, Type 2
Insulin secretion levels necessary for efficacy of an alpha-glucosidase inhibitor on glucose metabolism in patients with non-insulin-dependent diabetes mellitus.
Diabetes Mellitus, Type 2
Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus?
Diabetes Mellitus, Type 2
Long-term effect of alpha-glucosidase inhibitor on late dumping syndrome.
Diabetes Mellitus, Type 2
Long-term effectiveness of a new alpha-glucosidase inhibitor (BAY m1099-miglitol) in insulin-treated type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Long-term outcomes of adding alpha-glucosidase inhibitors in insulin-treated patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Long-term titrated-dose alpha-glucosidase inhibition in non-insulin-requiring Hispanic NIDDM patients.
Diabetes Mellitus, Type 2
Low-dose acarbose improves glycemic control in NIDDM patients without changes in insulin sensitivity.
Diabetes Mellitus, Type 2
Management of non-insulin-dependent diabetes mellitus.
Diabetes Mellitus, Type 2
Meta-analysis and critical review on the efficacy and safety of alpha-glucosidase inhibitors in Asian and non-Asian populations.
Diabetes Mellitus, Type 2
Meta-analysis of the impact of alpha-glucosidase inhibitors on incident diabetes and cardiovascular outcomes.
Diabetes Mellitus, Type 2
Mitiglinide: KAD 1229, S 21403.
Diabetes Mellitus, Type 2
New glucosidase inhibitors from an ayurvedic herbal treatment for type 2 diabetes: structures and inhibition of human intestinal maltase-glucoamylase with compounds from Salacia reticulata.
Diabetes Mellitus, Type 2
No effect of an alpha-glucosidase inhibitor on glucose metabolism in patients with non-insulin-dependent diabetes mellitus and low function of pancreatic beta cells.
Diabetes Mellitus, Type 2
Oral antidiabetic agents. The emergence of alpha-glucosidase inhibitors.
Diabetes Mellitus, Type 2
Oral hypoglycemic agents: insulin secretagogues, alpha-glucosidase inhibitors and insulin sensitizers.
Diabetes Mellitus, Type 2
Pharmacokinetics of oral antihyperglycaemic agents in patients with renal insufficiency.
Diabetes Mellitus, Type 2
Pharmacologic management of the older patient with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Phenolic-linked variation in strawberry cultivars for potential dietary management of hyperglycemia and related complications of hypertension.
Diabetes Mellitus, Type 2
Pioglitazone produces rapid and persistent reduction of vascular inflammation in patients with hypertension and type 2 diabetes mellitus who are receiving angiotensin II receptor blockers.
Diabetes Mellitus, Type 2
Pioglitazone: a review of Japanese clinical studies.
Diabetes Mellitus, Type 2
Pneumatosis cystoides intestinalis of the ascending colon related to acarbose treatment: a case report.
Diabetes Mellitus, Type 2
Potential antiradical and alpha-glucosidase inhibitors from Ecklonia maxima (Osbeck) Papenfuss.
Diabetes Mellitus, Type 2
Pu-erh tea polysaccharides decrease blood sugar by inhibition of ?-glucosidase activity in vitro and in mice.
Diabetes Mellitus, Type 2
Punica granatum flower extract, a potent alpha-glucosidase inhibitor, improves postprandial hyperglycemia in Zucker diabetic fatty rats.
Diabetes Mellitus, Type 2
Reappraisal of the pharmacologic approach to treatment of type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Relationship between gastric emptying and an alpha-glucosidase inhibitor effect on postprandial hyperglycemia in NIDDM patients.
Diabetes Mellitus, Type 2
Review: alpha-glucosidase inhibitors improve glycemic control but have uncertain effects on patient-important outcomes in type 2 diabetes.
Diabetes Mellitus, Type 2
Safety, tolerability and efficacy of lixisenatide in combination with oral antidiabetic treatment in Japanese patients with type 2 diabetes: An open-label, multicenter study.
Diabetes Mellitus, Type 2
Sex-dependent Differences in Liver and Gut Metabolomic Profiles with Acarbose and Calorie Restriction in C57BL/6 Mice.
Diabetes Mellitus, Type 2
Starch digestion, large-bowel fermentation and intestinal mucosal cell proliferation in rats treated with the alpha-glucosidase inhibitor acarbose.
Diabetes Mellitus, Type 2
Study of the inhibition of two human maltase-glucoamylases catalytic domains by different ?-glucosidase inhibitors.
Diabetes Mellitus, Type 2
Synergisms in Alpha-glucosidase Inhibition and Antioxidant Activity of Camellia sinensis L. Kuntze and Eugenia uniflora L. Ethanolic Extracts.
Diabetes Mellitus, Type 2
Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
The alpha-glucosidase inhibitor acarbose prevents obesity and simple steatosis in sequestosome 1/A170/p62 deficient mice.
Diabetes Mellitus, Type 2
The alpha-glucosidase inhibitor acarbose reduces the net electronegative charge of low-density lipoprotein in patients with newly diagnosed type 2 diabetes.
Diabetes Mellitus, Type 2
The alpha-glucosidase inhibitor miglitol decreases glucose fluctuations and inflammatory cytokine gene expression in peripheral leukocytes of Japanese patients with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
The clinical efficacy of a second-generation alpha-glucosidase inhibitor in non-insulin-dependent diabetic patients.
Diabetes Mellitus, Type 2
The effect of a very low dose of tolbutamide combined with an alpha-glucosidase inhibitor in non-insulin-dependent diabetes mellitus.
Diabetes Mellitus, Type 2
The effect of an alpha-glucosidase inhibitor and insulin on glucose metabolism and lipid profiles in non-insulin-dependent diabetes mellitus.
Diabetes Mellitus, Type 2
The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone.
Diabetes Mellitus, Type 2
The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial.
Diabetes Mellitus, Type 2
The hypoglycemic activity of Euclea undulata Thunb. var. myrtina (Ebenaceae) root bark evaluated in a streptozotocinnicotinamide induced type 2 diabetes rat model
Diabetes Mellitus, Type 2
The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus.
Diabetes Mellitus, Type 2
The synthesis and biological evaluation of 1-C-alkyl-L-arabinoiminofuranoses, a novel class of ?-glucosidase inhibitors.
Diabetes Mellitus, Type 2
The use of insulin secretagogues in the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
Treatment of type 2 diabetes mellitus in children and adolescents.
Diabetes Mellitus, Type 2
Type 2 diabetes mellitus: what is the optimal treatment regimen?
Diabetes Mellitus, Type 2
Use of an alpha-glucosidase inhibitor to synchronize sugar absorption with delayed insulin secretion in a patient with non-insulin-dependent diabetes mellitus.
Diabetes Mellitus, Type 2
Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance.
Diabetes Mellitus, Type 2
[Acarbose (glucobai) effects on lipid metabolism in patients with non-insulin dependent diabetes mellitus]
Diabetes Mellitus, Type 2
[Alpha-glucosidase inhibitor and insulin sensitizer combination therapy in NIDDM]
Diabetes Mellitus, Type 2
[Alpha-glucosidase inhibitor for the prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese subjects with impaired glucose tolerance]
Diabetes Mellitus, Type 2
[Clinical trials to evaluate interventions aimed to prevent or delay the development of diabetes in high risk IGT]
Diabetes Mellitus, Type 2
[Current status of the treatment of type 2 diabetes mellitus. Alpha-glucosidase inhibitors]
Diabetes Mellitus, Type 2
[Efficacy of combination therapy of alpha-glucosidase inhibitor and insulin sensitizer in patients with type 2 diabetes]
Diabetes Mellitus, Type 2
[Hypoglycemia in the diabetes treatment - risk minimization with dipeptidyl peptidase-4 inhibitors].
Diabetes Mellitus, Type 2
[Info-Meeting. Pharmacologic prevention of the progression from impaired glucose tolerance to type 2 diabetes: favorable effects of metformin and acarbose]
Diabetes Mellitus, Type 2
[Molecular targets for new drug discovery to treat type 2 diabetes and obesity]
Diabetes Mellitus, Type 2
[Non-insulin-dependent diabetes mellitus associated with nonalcoholic liver cirrhosis: an evaluation of treatment with the intestinal alpha-glucosidase inhibitor acarbose]
Diabetes Mellitus, Type 2
[Occurrence of ileus after voglibose treatment in an elderly diabetic patient with gait disturbance caused by cerebral hemorrhage]
Diabetes Mellitus, Type 2
[Pitfalls in treatment with oral antidiabetic agents]
Diabetes Mellitus, Type 2
[Synthetic medicinal chemistry of the biomolecular components mimics].
Diabetes Mellitus, Type 2
[The alpha-glucosidase inhibitor miglitol for the treatment of type 2 diabetes mellitus in the doctor's office]
Diabetes Mellitus, Type 2
[Treatment of type 2 diabetes mellitus with the alpha-glucosidase inhibitor Miglitol in the doctor's office]
Diabetes Mellitus, Type 2
[Use of oral hypoglycemic agents in patients with chronic kidney failure.]
Diabetic Ketoacidosis
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2016 EXECUTIVE SUMMARY.
Diabetic Ketoacidosis
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY.
Diabetic Ketoacidosis
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2020 EXECUTIVE SUMMARY.
Diabetic Neuropathies
Pneumatosis cystoides intestinalis of the ascending colon related to acarbose treatment: a case report.
Diabetic Retinopathy
Macrophage foam cell formation is augmented in serum from patients with diabetic angiopathy.
Diphtheria
STUDIES ON BACTERIAL ENZYMES : VI. THE MALTASE OF THE DIPHTHERIA BACILLUS.
Disorders of Excessive Somnolence
Sleep-related obstructive and nonobstructive apneas and neurologic disorders.
Diverticulum
alpha-Glucosidase of oyster (Crassostrea gigas) digestive diverticula.
Dumping Syndrome
Acute and long-term effect of alpha-glucosidase inhibitor on dumping syndrome in a patient after a vagotomy and pyloric surgery.
Dumping Syndrome
Concurrent Therapy with a Low-carbohydrate Diet and Miglitol Remarkably Improved the Postprandial Blood Glucose and Insulin Levels in a Patient with Reactive Hypoglycemia due to Late Dumping Syndrome.
Dumping Syndrome
Effect of acarbose on the 24-hour blood glucose profile and pattern of carbohydrate absorption.
Dumping Syndrome
Long-term effect of alpha-glucosidase inhibitor on late dumping syndrome.
Dumping Syndrome
[The effect of alpha-glucosidase inhibitor on burning epigastralgia in dumping syndrome: a case report]
Duodenal Ulcer
Study of enzyme activities in the descending part of the duodenum in patients of duodenal ulcer.
Duodenitis
Low activities of disaccharidases associated with inflamed duodenal bulb mucosa.
Dyslipidemias
Improvement of insulin sensitivity and dyslipidemia with a new alpha-glucosidase inhibitor, voglibose, in nondiabetic hyperinsulinemic subjects.
Dyslipidemias
In vitro inhibitory effects of Limonium contortirameum and L. virgatum extracts from sardinia on alpha-amylase, alpha-glucosidase and pancreatic lipase.
Dyspnea
Optoelectronic plethysmography as an alternative method for the diagnosis of unilateral diaphragmatic weakness.
Encephalomyelitis, Autoimmune, Experimental
Inhibition of experimental allergic encephalomyelitis by the alpha-glucosidase inhibitor castanospermine.
Enteritis
[Maltase activity in the small intestine during chronic enteritis]
Enteritis
[Maltase activity of the small intestine in chronic enteritis]
Epididymitis
The influence of inflammation of the human male genital tract on secretion of the seminal markers alpha-glucosidase, glycerophosphocholine, carnitine, fructose and citric acid.
Epstein-Barr Virus Infections
A rare presentation of childhood pompe disease: cardiac involvement provoked by Epstein-Barr virus infection.
Exocrine Pancreatic Insufficiency
Influence of exocrine and endocrine pancreatic function on intestinal brush border enaymatic activities.
Fabry Disease
Biological properties of D- and L-1-deoxyazasugars.
Fabry Disease
Biotherapeutic target or sink: analysis of the macrophage mannose receptor tissue distribution in murine models of lysosomal storage diseases.
Fabry Disease
Lysosomal storage diseases.
Fabry Disease
Uptake of lysosomal enzymes by human fibroblasts: lack of uptake of fungal or plant glycosidases in comparison with a mammalian enzyme.
Fatty Liver
alpha-Glucosidase inhibitor acarbose and sequestome 1/A170/p62 deficient mice: A promising therapy and unique model for non-alcoholic fatty liver disease.
Fatty Liver
Inhibitory effect of a new alpha-glucosidase inhibitor on fatty liver in Zucker fatty rats.
Fatty Liver
[The effect of an alpha-glucosidase inhibitor on fatty liver in obesity]
Fetal Growth Retardation
Effect of intrauterine growth retardation on the activities of fetal intestinal enzymes in rats.
Fructose Intolerance
Fructose-free diet effects on intestinal alpha-glucosidase activities in hereditary fructose intolerance.
Gastroenteritis
The role of probiotic cultures in the control of gastrointestinal health.
Gastroesophageal Reflux
Brush border enzyme activities in relation to histological lesion in pediatric celiac disease.
Gastrointestinal Diseases
The Role of Disaccharidase Deficiencies in Functional Abdominal Pain Disorders-A Narrative Review.
Gastrointestinal Diseases
The role of probiotic cultures in the control of gastrointestinal health.
Gaucher Disease
Lysosomal storage diseases.
Genetic Diseases, Inborn
Infantile-onset Pompe disease: Diagnosis and management.
Giardiasis
Disaccharidase deficiencies in Mongolian gerbils (Meriones unguiculatus) protected against Giardia lamblia.
Giardiasis
[Enzymes and histology of the intestinal mucosa of breast-fed African infants]
Glioblastoma
Activity of glycogen depolymerizing enzymes in extracts from brain tumor tissue (anaplastic astrocytoma and glioblastoma multiforme).
Glomerulonephritis, Membranous
Microdomains of distinctive glycoprotein composition in the kidney proximal tubule brush border.
glucan 1,4-alpha-glucosidase deficiency
A cross-sectional single-centre study on Pompe disease in 42 German patients: Molecular analysis of the GAA gene, manifestation and genotype-phenotype correlations.
glucan 1,4-alpha-glucosidase deficiency
alpha-Glucosidase isoenzymes in normal and acid maltase-deficient human skeletal muscles.
glucan 1,4-alpha-glucosidase deficiency
Genotype-phenotype correlation in adult-onset acid maltase deficiency.
glucan 1,4-alpha-glucosidase deficiency
Immunocytochemical analysis of normal and acid maltase-deficient muscle cultures.
glucan 1,4-alpha-glucosidase deficiency
Infantile-onset Pompe disease: Diagnosis and management.
glucan 1,4-alpha-glucosidase deficiency
Late-onset acid maltase deficiency. Biochemical studies of leukocytes.
glucan 1,4-alpha-glucosidase deficiency
Multiple neutral maltase activities in normal and acid maltase-deficient human muscle.
glucan 1,4-alpha-glucosidase deficiency
New kind of cytoplasmic inclusions of plasma cells in acid maltase deficiency.
glucan 1,4-alpha-glucosidase deficiency
Patients with functional bowel disorder have disaccharidase deficiency: A single-center study from Russia.
glucan 1,4-alpha-glucosidase deficiency
Reappearance of embryonic neutral alpha-glucosidase isoenzyme in acid maltase-deficient muscle of Japanese quail.
glucan 1,4-alpha-glucosidase deficiency
Selective vacuolar myopathy with atrophy of type II fibers. Occurrence in a childhood case of acid maltase deficiency.
glucan 1,4-alpha-glucosidase deficiency
Small intestinal glucoamylase deficiency and starch malabsorption: a newly recognized alpha-glucosidase deficiency in children.
glucan 1,4-alpha-glucosidase deficiency
Treatment of acid maltase deficiency with a diet high in branched-chain amino acids.
glucan 1,4-alpha-glucosidase deficiency
Tris discriminates between the different alpha-glucosidase activities from extracts of human neutrophils.
glucan 1,4-alpha-glucosidase deficiency
[Disaccharidase deficiency and functional bowel diseases].
Glucose Intolerance
Acarbose is a promising therapeutic strategy for the treatment of patients with nonalcoholic steatohepatitis (NASH).
Glucose Intolerance
Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.
Glucose Intolerance
Acarbose, an alpha-glucosidase inhibitor, decreases aortic gene expression and serum levels of monocyte chemoattractant protein-1 in fructose-fed rats.
Glucose Intolerance
Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose.
Glucose Intolerance
Alpha-glucosidase inhibitors in the early treatment of type 2 diabetes.
Glucose Intolerance
Comparative safety of newer oral antidiabetic drugs.
Glucose Intolerance
Does Treatment of Impaired Glucose Tolerance Improve Cardiovascular Outcomes in Patients with Previous Myocardial Infarction?
Glucose Intolerance
Effect of acarbose on glucose intolerance in patients with non-insulin-dependent diabetes mellitus.
Glucose Intolerance
Effect of inhibition of alpha-glucosidase on age-related glucose intolerance and pancreatic atrophy in rats.
Glucose Intolerance
Effects of a late evening snack combined with alpha-glucosidase inhibitor on liver cirrhosis.
Glucose Intolerance
Effects of acarbose on proinsulin and insulin secretion and their potential significance for the intermediary metabolism and cardiovascular system.
Glucose Intolerance
Impaired glucose homeostasis in young adult thalassemic patients: a pilot study with acarbose.
Glucose Intolerance
Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
Glucose Intolerance
Plasma BNP Levels and Diuretics Use as Predictors of Cardiovascular Events in Patients with Myocardial Infarction and Impaired Glucose Tolerance.
Glucose Intolerance
Potential of alpha-glucosidase inhibitors in elderly patients with diabetes mellitus and impaired glucose tolerance.
Glucose Intolerance
The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance.
Glucose Intolerance
The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus.
Glucose Intolerance
Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance.
Glucose Intolerance
[Alpha-glucosidase inhibitor for the prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese subjects with impaired glucose tolerance]
Glucose Intolerance
[Cardiovascular effects of oral hypoglycemie drugs]
Glucose Intolerance
[Effects of acarbose, alpha-glucosidase inhibitor in treatment of impaired glucose tolerance]
Glucose Intolerance
[Effects of voglibose, alpha-glucosidase inhibitor in treatment of impaired glucose tolerance]
Glucose Intolerance
[Info-Meeting. Pharmacologic prevention of the progression from impaired glucose tolerance to type 2 diabetes: favorable effects of metformin and acarbose]
Glucose Intolerance
[Prevention of the manifestation of diabetes in the elderly in the presymptomatic stage]
Glycogen Storage Disease
A micro-radiochemical assay for alpha-1,4-glucosidase and its use in the assessment of type II glycogenosis (Pompe's disease).
Glycogen Storage Disease
A microfluorometric assay of leukocyte alpha-1,4-glucosidase.
Glycogen Storage Disease
A sensitive semi-automated kinetic assay of alpha-D-glucosidase for the prenatal diagnosis of type 2 glycogenosis (Pompe's disease).
Glycogen Storage Disease
Acid alpha-glucosidase deficiency (glycogenosis type II, Pompe disease).
Glycogen Storage Disease
Adeno-associated virus-mediated transfer of human acid maltase gene results in a transient reduction of glycogen accumulation in muscle of Japanese quail with acid maltase deficiency.
Glycogen Storage Disease
Adult forms of glycogenosis type II. A defect in an early stage of acid alpha-glucosidase realization.
Glycogen Storage Disease
Age-related decline in muscle strength and power output in acid 1-4 alpha-glucosidase knockout mice.
Glycogen Storage Disease
Alglucosidase alfa enzyme replacement therapy as a therapeutic approach for glycogen storage disease type III.
Glycogen Storage Disease
Alglucosidase alfa treatment alleviates liver disease in a mouse model of glycogen storage disease type IV.
Glycogen Storage Disease
Alpha-glucosidase administration: experiences in two patients with glycogen storage disease compared with animal experiments.
Glycogen Storage Disease
alpha1,4-Glucosidase-albumin polymers: in vitro properties and advantages for enzyme replacement therapy.
Glycogen Storage Disease
Angiocardiographic and enzyme studies in a patient with type II glycogenosis (Pompe's disease). A case report.
Glycogen Storage Disease
Biochemical genetics of the Lapland dog model of glycogen storage disease type II (acid alpha-glucosidase deficiency).
Glycogen Storage Disease
Bovine generalised glycogenosis type II. Uptake of lysosomal alpha-glucosidase by cultured skeletal muscle and reversal of glycogen accumulation.
Glycogen Storage Disease
Broad spectrum of Pompe disease in patients with the same c.-32-13T->G haplotype.
Glycogen Storage Disease
Canine glycogen storage disease type II. A biochemical study of an acid alpha-glucosidase-deficient Lapland dog.
Glycogen Storage Disease
Cell-free translation of human lysosomal alpha-glucosidase: evidence for reduced precursor synthesis in an adult patient with glycogenosis type II.
Glycogen Storage Disease
Clinical diversity in glycogenosis type II. Biosynthesis and in situ localization of acid alpha-glucosidase in mutant fibroblasts.
Glycogen Storage Disease
Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients.
Glycogen Storage Disease
Common antigenicity for two glycosidases.
Glycogen Storage Disease
Comparative pathology of the canine model of glycogen storage disease type II (Pompe's disease).
Glycogen Storage Disease
Correction of multiple striated muscles in murine Pompe disease through adeno-associated virus-mediated gene therapy.
Glycogen Storage Disease
Decreased activity of acid alpha-glucosidase in a patient with persistent periocular swelling after infusions of hydroxyethyl starch.
Glycogen Storage Disease
Diagnosis of Pompe disease: muscle biopsy vs blood-based assays.
Glycogen Storage Disease
Differential muscular glycogen clearance after enzyme replacement therapy in a mouse model of Pompe disease.
Glycogen Storage Disease
Dominantly inherited cardioskeletal myopathy with lysosomal glycogen storage and normal acid maltase levels.
Glycogen Storage Disease
Enzyme replacement therapy for infantile Pompe disease during the critical period and identification of a novel mutation.
Glycogen Storage Disease
Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial.
Glycogen Storage Disease
Evidence of molecular heterogeneity for generalised glycogenosis between and within breeds of cattle.
Glycogen Storage Disease
Extended phenotype description and new molecular findings in late onset glycogen storage disease type II: a northern Italy population study and review of the literature.
Glycogen Storage Disease
First trimester diagnosis of Pompe's disease (glycogenosis type II) with normal outcome: assay of acid alpha-glucosidase in chorionic villous biopsy using antibodies.
Glycogen Storage Disease
Frequent mutation in Chinese patients with infantile type of GSD II in Taiwan: evidence for a founder effect.
Glycogen Storage Disease
Genetic defects in patients with glycogenosis type II (acid maltase deficiency).
Glycogen Storage Disease
Genotyping Brahman cattle for generalised glycogenosis.
Glycogen Storage Disease
Genotyping shorthorn cattle for generalised glycogenosis.
Glycogen Storage Disease
Glycogen storage disease type I. Results of treatment with frequent daytime feeding, combined with nocturnal intragastric feeding and with administration of an alpha-glucosidase inhibitor.
Glycogen Storage Disease
Glycogenosis type II (acid maltase deficiency).
Glycogen Storage Disease
Heterozygote detection in a family of Lapland dogs with a recessively inherited metabolic disease: canine glycogen storage disease type II.
Glycogen Storage Disease
Hydrostatic isolated limb perfusion with adeno-associated virus vectors enhances correction of skeletal muscle in Pompe disease.
Glycogen Storage Disease
Identification of a de novo point mutation resulting in infantile form of Pompe's disease.
Glycogen Storage Disease
Identification of a small deletion in one allele of patients with infantile form of glycogen storage disease type II.
Glycogen Storage Disease
Immunochemical studies of human acid alpha-1,4-glucosidase in type II glycogenosis.
Glycogen Storage Disease
Infantile-onset Pompe disease: Diagnosis and management.
Glycogen Storage Disease
Inhibition of bovine alpha-glucosidase by Castanospermum australe and its effect on the biochemical identification of heterozygotes for generalised glycogenosis type II (Pompe's disease) in cattle.
Glycogen Storage Disease
Late-Onset Glycogen Storage Disease Type II (Pompe's Disease) with a Novel Mutation: A Malaysian Experience.
Glycogen Storage Disease
Leucocyte alpha-1,4- and alpha-1,6-glucosidase activities towards oligosaccharides in late onset glycogenosis type II.
Glycogen Storage Disease
Lymphocyte alpha-glucosidase in late-onset glycogenosis type II.
Glycogen Storage Disease
Lysosomal glycogen storage mimicking the cytological picture of Pompe's disease as induced in rats by injection of an alpha-glucosidase inhibitor. I. Alterations in liver.
Glycogen Storage Disease
Molecular diagnosis of German patients with late-onset glycogen storage disease type II.
Glycogen Storage Disease
New insights into therapeutic options for Pompe disease.
Glycogen Storage Disease
Nosology of lysosomal glycogen storage diseases without in vitro acid maltase deficiency. Delineation of a neonatal form.
Glycogen Storage Disease
Partial characterization of leucocyte alpha-glucosidase in late onset glycogenosis type II.
Glycogen Storage Disease
Pompe disease: a review of the current diagnosis and treatment recommendations in the era of enzyme replacement therapy.
Glycogen Storage Disease
Preparation of monoclonal antibodies against acid alpha-D-glucosidase for study of Chinese glycogenosis type II patients.
Glycogen Storage Disease
Progress in Enzyme Replacement Therapy in Glycogen Storage Disease Type II.
Glycogen Storage Disease
Properties of the alpha-glucosidase from various human tissues in relation to glycogenosis type II (Pompe's disease).
Glycogen Storage Disease
Screening for Pompe disease using a rapid dried blood spot method: experience of a clinical diagnostic laboratory.
Glycogen Storage Disease
Simultaneous absence of alpha-1,4-glucosidase and alpha-1,6-glucosidase activities (pH 4) in tissues of children with type II glycogen storage disease.
Glycogen Storage Disease
The electrophoretic pattern and activities of acid and neutral maltase of cultivated fibroblasts and amniotic fluid cells from controls and patients with the variant of glycogen storage disease type II (Pompe's disease).
Glycogen Storage Disease
Therapeutic approaches in glycogen storage disease type II/Pompe Disease.
Glycogen Storage Disease
Tris discriminates between the different alpha-glucosidase activities from extracts of human neutrophils.
Glycogen Storage Disease
Two extremes of the clinical spectrum of glycogen storage disease type II in one family: a matter of genotype.
Glycogen Storage Disease
Ultrastructure of the eye in fetal type II glycogenosis (Pompe's disease).
Glycogen Storage Disease
Using human Pompe disease-induced pluripotent stem cell-derived neural cells to identify compounds with therapeutic potential.
Glycogen Storage Disease
Zonal differences of alpha-glucosidases in human kidney: studies in controls and in patients with glycogenosis type II.
Glycogen Storage Disease
[Biochemical diagnosis of glycogenosis type II (acid maltase deficiency) (author's transl)]
Glycogen Storage Disease
[Cardiomuscular lysosomal glycogenosis in adults without known enzyme deficiency. A cause of familial myocardiopathy and lysosomal glycogen overload with normal acid maltase]
Glycogen Storage Disease
[Characterization of alpha-glucosidase in skin fibroblasts in the diagnosis of glycogenosis type 2 (Pompe disease)]
Glycogen Storage Disease
[Heterogeneity of glycogenosis with alpha-1,4-glucosidase deficiency: enzymatic studies in three families (author's transl)]
Glycogen Storage Disease
[Immunochemical study of acid alpha-1,4-glucosidase in 7 patients with type II glycogenosis]
Glycogen Storage Disease
[Muscular glycogenosis caused by alpha-1,4-glucosidase deficiency simulating progressive muscular dystrophy. (Clinical and enzyme study. Optic and electron microscopy)]
Glycogen Storage Disease
[ON A SPECIAL FORM OF GIERKE'S GLYCOGENOSIS WITH INCREASED ALPHA-GLUCOSIDASE ACTIVITY IN THE LIVER AND COMPLETE LACK OF GLUCOSE-6-PHOSPHATASE.]
Glycogen Storage Disease
[Pompe and his disease].
Glycogen Storage Disease
[Pseudodystrophic muscle glycogenosis in adults. (Acid maltase deficiency syndrome) (author's transl)]
Glycogen Storage Disease
[Tests for the detection of inborn errors of metabolism--urinary alpha-glucosidase analysis for the detection of glycogen storage disease type II (author's transl)]
Glycogen Storage Disease Type I
Glycogen storage disease type I. Results of treatment with frequent daytime feeding, combined with nocturnal intragastric feeding and with administration of an alpha-glucosidase inhibitor.
Glycogen Storage Disease Type II
36 months observational clinical study of 38 adult Pompe disease patients under alglucosidase alfa enzyme replacement therapy.
Glycogen Storage Disease Type II
A 4-Year Observational Clinical Study of 24 Adult Pompe Disease Patients under Alglucosidase Alfa Enzyme Replacement Therapy.
Glycogen Storage Disease Type II
A case of adult Pompe disease presenting with severe fatigue and selective involvement of type 1 muscle fibers.
Glycogen Storage Disease Type II
A cross-sectional single-centre study on Pompe disease in 42 German patients: Molecular analysis of the GAA gene, manifestation and genotype-phenotype correlations.
Glycogen Storage Disease Type II
A fluorometric assay of alpha-glucosidase and its application in the study of Pompe's disease.
Glycogen Storage Disease Type II
A micro-radiochemical assay for alpha-1,4-glucosidase and its use in the assessment of type II glycogenosis (Pompe's disease).
Glycogen Storage Disease Type II
A microfluorometric assay of leukocyte alpha-1,4-glucosidase.
Glycogen Storage Disease Type II
A molecular analysis of the GAA gene and clinical spectrum in 38 patients with Pompe disease in Japan.
Glycogen Storage Disease Type II
A new assay for fast, reliable CRIM status determination in infantile-onset Pompe disease.
Glycogen Storage Disease Type II
A new resorufin-based alpha-glucosidase assay for high-throughput screening.
Glycogen Storage Disease Type II
A Phase 4 Prospective Study in Patients with Adult Pompe Disease Treated with Alglucosidase Alfa.
Glycogen Storage Disease Type II
A randomized study of alglucosidase alfa in late-onset Pompe's disease.
Glycogen Storage Disease Type II
A rare presentation of childhood pompe disease: cardiac involvement provoked by Epstein-Barr virus infection.
Glycogen Storage Disease Type II
A review of treatment of Pompe disease in infants.
Glycogen Storage Disease Type II
Abnormal mannose-6-phosphate receptor trafficking impairs recombinant alpha-glucosidase uptake in Pompe disease fibroblasts.
Glycogen Storage Disease Type II
Abnormal trafficking of sarcolemmal proteins in alpha-glucosidase deficiency.
Glycogen Storage Disease Type II
Acid alpha-glucosidase deficiency (glycogenosis type II, Pompe disease).
Glycogen Storage Disease Type II
Acid maltase deficiency and related myopathies.
Glycogen Storage Disease Type II
Adeno-associated virus-mediated transfer of human acid maltase gene results in a transient reduction of glycogen accumulation in muscle of Japanese quail with acid maltase deficiency.
Glycogen Storage Disease Type II
Adult forms of glycogenosis type II. A defect in an early stage of acid alpha-glucosidase realization.
Glycogen Storage Disease Type II
Adult Pompe disease: Clinical manifestations and outcome of the first Greek patients receiving enzyme replacement therapy.
Glycogen Storage Disease Type II
Adult-onset acid maltase deficiency. Case report of an adult with severe respiratory difficulty.
Glycogen Storage Disease Type II
Age-related decline in muscle strength and power output in acid 1-4 alpha-glucosidase knockout mice.
Glycogen Storage Disease Type II
Alglucosidase alfa and Pompe disease: still going strong?
Glycogen Storage Disease Type II
Alglucosidase alfa therapy for Pompe disease in pregnancy - Case report.
Glycogen Storage Disease Type II
Alglucosidase alfa: Long term use in the treatment of patients with Pompe disease.
Glycogen Storage Disease Type II
Alglucosidase alfa: new drug. Pompe disease: a short-term benefit.
Glycogen Storage Disease Type II
alpha-glucosidase (CHO) (Genzyme).
Glycogen Storage Disease Type II
alpha-glucosidase activity in human leucocytes: choice of lymphocytes for the diagnosis of Pompe's disease and the carrier state.
Glycogen Storage Disease Type II
alpha-Glucosidase deficiency (Pompe's disease).
Glycogen Storage Disease Type II
Alpha-glucosidase deficiency and basilar artery aneurysm: report of a sibship.
Glycogen Storage Disease Type II
Alpha-glucosidase deficiency in a child.
Glycogen Storage Disease Type II
alpha-Glucosidase deficiency in generalized glycogenstorage disease (Pompe's disease).
Glycogen Storage Disease Type II
alpha-Glucosidase in Pompe's disease.
Glycogen Storage Disease Type II
alpha-Glucosidase isoenzymes in normal and acid maltase-deficient human skeletal muscles.
Glycogen Storage Disease Type II
Amniotic cell 4-methylumbelliferyl-alpha-glucosidase activity for prenatal diagnosis of Pompe's disease.
Glycogen Storage Disease Type II
An individually, modified approach to desensitize infants and young children with Pompe disease, and significant reactions to alglucosidase alfa infusions.
Glycogen Storage Disease Type II
Antisense Oligonucleotide-mediated Suppression of Muscle Glycogen Synthase 1 Synthesis as an Approach for Substrate Reduction Therapy of Pompe Disease.
Glycogen Storage Disease Type II
Assessing metabolic profiles in human myoblasts from patients with late-onset Pompe disease.
Glycogen Storage Disease Type II
At-Risk Testing for Pompe Disease Using Dried Blood Spots: Lessons Learned for Newborn Screening.
Glycogen Storage Disease Type II
Attitudes and expectations of patients with neuromuscular diseases about their participation in a clinical trial.
Glycogen Storage Disease Type II
Atypical immunologic response in a patient with CRIM-negative Pompe disease.
Glycogen Storage Disease Type II
Biochemical and pharmacological characterization of different recombinant acid alpha-glucosidase preparations evaluated for the treatment of Pompe disease.
Glycogen Storage Disease Type II
Biochemical genetics of the Lapland dog model of glycogen storage disease type II (acid alpha-glucosidase deficiency).
Glycogen Storage Disease Type II
Biopsy-proven alpha-glucosidase deficiency with normal lymphocyte enzyme activity.
Glycogen Storage Disease Type II
Biosynthesis of acid alpha-glucosidase in late-onset forms of glycogenosis type II (Pompe's disease).
Glycogen Storage Disease Type II
Biotherapeutic target or sink: analysis of the macrophage mannose receptor tissue distribution in murine models of lysosomal storage diseases.
Glycogen Storage Disease Type II
Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease.
Glycogen Storage Disease Type II
Bovine generalised glycogenosis type II. Uptake of lysosomal alpha-glucosidase by cultured skeletal muscle and reversal of glycogen accumulation.
Glycogen Storage Disease Type II
Broad spectrum of Pompe disease in patients with the same c.-32-13T->G haplotype.
Glycogen Storage Disease Type II
Canine glycogen storage disease type II. A biochemical study of an acid alpha-glucosidase-deficient Lapland dog.
Glycogen Storage Disease Type II
Cardiac remodeling after enzyme replacement therapy with acid alpha-glucosidase for infants with Pompe disease.
Glycogen Storage Disease Type II
Cardiac responses in paediatric Pompe disease in the ADVANCE patient cohort.
Glycogen Storage Disease Type II
Cardiopulmonary exercise test to quantify enzyme replacement response in pediatric Pompe disease.
Glycogen Storage Disease Type II
Cell-free translation of human lysosomal alpha-glucosidase: evidence for reduced precursor synthesis in an adult patient with glycogenosis type II.
Glycogen Storage Disease Type II
Cessation and resuming of alglucosidase alfa in Pompe disease: a retrospective analysis.
Glycogen Storage Disease Type II
Challenges in treating Pompe disease: an industry perspective.
Glycogen Storage Disease Type II
Characterization of the molecular defect in infantile and adult acid alpha-glucosidase deficiency fibroblasts.
Glycogen Storage Disease Type II
Clinical and metabolic correction of pompe disease by enzyme therapy in acid maltase-deficient quail.
Glycogen Storage Disease Type II
Clinical characteristics and genotypes in the ADVANCE baseline data set, a comprehensive cohort of US children and adolescents with Pompe disease.
Glycogen Storage Disease Type II
Clinical consequences of reduced dosing schedule during treatment of a patient with Pompe's disease.
Glycogen Storage Disease Type II
Clinical diversity in glycogenosis type II. Biosynthesis and in situ localization of acid alpha-glucosidase in mutant fibroblasts.
Glycogen Storage Disease Type II
Clinical efficacy of the enzyme replacement therapy in patients with late-onset Pompe disease: a systematic review and a meta-analysis.
Glycogen Storage Disease Type II
Clinical guidelines for late-onset Pompe disease.
Glycogen Storage Disease Type II
Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients.
Glycogen Storage Disease Type II
Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease.
Glycogen Storage Disease Type II
Common antigenicity for two glycosidases.
Glycogen Storage Disease Type II
Comparative pathology of the canine model of glycogen storage disease type II (Pompe's disease).
Glycogen Storage Disease Type II
Correcting Neuromuscular Deficits With Gene Therapy in Pompe Disease.
Glycogen Storage Disease Type II
Correction of multiple striated muscles in murine Pompe disease through adeno-associated virus-mediated gene therapy.
Glycogen Storage Disease Type II
Correction/mutation of acid alpha-D-glucosidase gene by modified single-stranded oligonucleotides: in vitro and in vivo studies.
Glycogen Storage Disease Type II
Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in adult patients with Pompe disease.
Glycogen Storage Disease Type II
Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in classic-infantile patients with Pompe disease.
Glycogen Storage Disease Type II
Cystic fibrosis newborn screening: a model for neuromuscular disease screening?
Glycogen Storage Disease Type II
Decreased activity of acid alpha-glucosidase in a patient with persistent periocular swelling after infusions of hydroxyethyl starch.
Glycogen Storage Disease Type II
Desensitisation of the youngest patient with Pompe disease in response to alglucosidase alfa.
Glycogen Storage Disease Type II
Desensitization of an adult patient with Pompe disease and a history of anaphylaxis to alglucosidase alfa.
Glycogen Storage Disease Type II
Desensitization of two young patients with infantile-onset Pompe disease and severe reactions to alglucosidase alfa.
Glycogen Storage Disease Type II
Detection of human acid alpha-glucosidase in fibroblasts using monoclonal antibodies in a biotin-avidin amplified ELISA.
Glycogen Storage Disease Type II
Diagnosis and treatment of late-onset Pompe disease in the Middle East and North Africa region: consensus recommendations from an expert group.
Glycogen Storage Disease Type II
Diagnosis of Pompe disease: muscle biopsy vs blood-based assays.
Glycogen Storage Disease Type II
Diagnosis of Pompe's disease in cultured skin fibroblasts and primary amniotic fluid cells using 4-methylumbelliferyl-alpha-D-glucopyranoside as substrate.
Glycogen Storage Disease Type II
Diagnosis of Pompe's disease using pyridylamino-maltooligosaccharides as substrates of alpha-1,4-glucosidase.
Glycogen Storage Disease Type II
Differential muscular glycogen clearance after enzyme replacement therapy in a mouse model of Pompe disease.
Glycogen Storage Disease Type II
Divergent clinical outcomes of alpha-glucosidase enzyme replacement therapy in two siblings with infantile-onset Pompe disease treated in the symptomatic or pre-symptomatic state.
Glycogen Storage Disease Type II
Earlier and higher dosing of alglucosidase alfa improve outcomes in patients with infantile-onset Pompe disease: Evidence from real-world experiences.
Glycogen Storage Disease Type II
Effect of enzyme replacement therapy with alglucosidase alfa (Myozyme®) in 12 patients with advanced late-onset Pompe disease.
Glycogen Storage Disease Type II
Effects of a higher dose of alglucosidase alfa on ventilator-free survival and motor outcome in classic infantile Pompe disease: an open-label single-center study.
Glycogen Storage Disease Type II
Effects of non-contractile inclusions on mechanical performance of skeletal muscle.
Glycogen Storage Disease Type II
Efficacy, safety profile, and immunogenicity of alglucosidase alfa produced at the 4,000-liter scale in US children and adolescents with Pompe disease: ADVANCE, a phase IV, open-label, prospective study.
Glycogen Storage Disease Type II
Electrocardiographic response to enzyme replacement therapy for Pompe disease.
Glycogen Storage Disease Type II
Endolysosomal N-glycan processing is critical to attain the most active form of the enzyme acid alpha-glucosidase.
Glycogen Storage Disease Type II
Enhanced enzyme activity after incubation with zinc can be used to distinguish heterozygotes of Pompe's disease.
Glycogen Storage Disease Type II
Enzyme inhibitory assay using monoclonal antibody against acid alpha-D-glucosidase in prenatal diagnosis to identify homozygotes of Pompe's disease.
Glycogen Storage Disease Type II
Enzyme replacement therapy desensitization in a child with infantile onset Pompe disease.
Glycogen Storage Disease Type II
Enzyme replacement therapy for infantile Pompe disease during the critical period and identification of a novel mutation.
Glycogen Storage Disease Type II
Enzyme replacement therapy for infantile-onset Pompe disease.
Glycogen Storage Disease Type II
Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review.
Glycogen Storage Disease Type II
Enzyme replacement therapy in late-onset Pompe's disease: a three-year follow-up.
Glycogen Storage Disease Type II
Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial.
Glycogen Storage Disease Type II
Enzyme replacement therapy with alglucosidase alfa in a late-onset Pompe disease patient during pregnancy.
Glycogen Storage Disease Type II
Enzyme replacement therapy with alglucosidase alfa in Pompe disease: Clinical experience with rate escalation.
Glycogen Storage Disease Type II
Enzyme therapy for pompe disease with recombinant human alpha-glucosidase from rabbit milk.
Glycogen Storage Disease Type II
Expression of lysosomal enzymes in human mutant fibroblast-chick erythrocyte heterokaryons.
Glycogen Storage Disease Type II
Extended phenotype description and new molecular findings in late onset glycogen storage disease type II: a northern Italy population study and review of the literature.
Glycogen Storage Disease Type II
First experience with enzyme replacement therapy during pregnancy and lactation in Pompe disease.
Glycogen Storage Disease Type II
First trimester diagnosis of Pompe's disease (glycogenosis type II) with normal outcome: assay of acid alpha-glucosidase in chorionic villous biopsy using antibodies.
Glycogen Storage Disease Type II
Four unreported types of glycans containing mannose-6-phosphate are heterogeneously attached at three sites (including newly found Asn 233) to recombinant human acid alpha-glucosidase that is the only approved treatment for Pompe disease.
Glycogen Storage Disease Type II
Frequent mutation in Chinese patients with infantile type of GSD II in Taiwan: evidence for a founder effect.
Glycogen Storage Disease Type II
Functional assessment tools in children with Pompe disease: A pilot comparative study to identify suitable outcome measures for the standard of care.
Glycogen Storage Disease Type II
Generalised glycogenosis in Brahman cattle.
Glycogen Storage Disease Type II
Generalized glycogenosis in beef shorthorn cattle--heterozygote detection.
Glycogen Storage Disease Type II
Genetic defects in patients with glycogenosis type II (acid maltase deficiency).
Glycogen Storage Disease Type II
Genotype-phenotype correlation in adult-onset acid maltase deficiency.
Glycogen Storage Disease Type II
Glycogen storage disease type II (Pompe disease)--influence of enzyme replacement therapy in adults.
Glycogen Storage Disease Type II
Glycogen storage disease type II in Israel.
Glycogen Storage Disease Type II
Glycogen storage disease types I and II: treatment updates.
Glycogen Storage Disease Type II
Glycogen storage diseases in animals and their potential value as models of human disease.
Glycogen Storage Disease Type II
Glycogenosis type II (acid maltase deficiency).
Glycogen Storage Disease Type II
Haemopoietic chimaerism: a complication in heterozygote detection tests for inherited defects in cattle.
Glycogen Storage Disease Type II
Heterozygote detection in a family of Lapland dogs with a recessively inherited metabolic disease: canine glycogen storage disease type II.
Glycogen Storage Disease Type II
High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa.
Glycogen Storage Disease Type II
High dose IVIG successfully reduces high rhGAA IgG antibody titers in a CRIM-negative infantile Pompe disease patient.
Glycogen Storage Disease Type II
Higher dosing of alglucosidase alfa improves outcomes in children with Pompe disease: a clinical study and review of the literature.
Glycogen Storage Disease Type II
Human lysosomal alpha-glucosidase: functional characterization of the glycosylation sites.
Glycogen Storage Disease Type II
Hydrostatic isolated limb perfusion with adeno-associated virus vectors enhances correction of skeletal muscle in Pompe disease.
Glycogen Storage Disease Type II
Identification of a de novo point mutation resulting in infantile form of Pompe's disease.
Glycogen Storage Disease Type II
Identification of a small deletion in one allele of patients with infantile form of glycogen storage disease type II.
Glycogen Storage Disease Type II
Identification of heterozygotes for glycogenosis 2 (acid maltase deficiency).
Glycogen Storage Disease Type II
Immune Modulation Therapy in a CRIM-Positive and IgG Antibody-Positive Infant with Pompe Disease Treated with Alglucosidase Alfa: A Case Report.
Glycogen Storage Disease Type II
Immunocytochemical analysis of normal and acid maltase-deficient muscle cultures.
Glycogen Storage Disease Type II
Immunological challenges and approaches to immunomodulation in Pompe disease: a literature review.
Glycogen Storage Disease Type II
Improved efficacy of a next-generation ERT in murine Pompe disease.
Glycogen Storage Disease Type II
Improvement in Cardiac Function With Enzyme Replacement Therapy in a Patient With Infantile-Onset Pompe Disease.
Glycogen Storage Disease Type II
Improvement of dysphagia in a child affected by Pompe disease treated with enzyme replacement therapy.
Glycogen Storage Disease Type II
Improvement with ongoing Enzyme Replacement Therapy in advanced late-onset Pompe disease: a case study.
Glycogen Storage Disease Type II
Infantile-onset Pompe disease: Diagnosis and management.
Glycogen Storage Disease Type II
Inhibition of alpha-glucosidase in cattle by Castanospermum australe: an attempted phenocopy of Pompe's disease.
Glycogen Storage Disease Type II
Inhibition of bovine alpha-glucosidase by Castanospermum australe and its effect on the biochemical identification of heterozygotes for generalised glycogenosis type II (Pompe's disease) in cattle.
Glycogen Storage Disease Type II
Inhibitory effect of phloroglucinol on ?-glucosidase: Kinetics and molecular dynamics simulation integration study.
Glycogen Storage Disease Type II
Late-onset acid maltase deficiency. Biochemical studies of leukocytes.
Glycogen Storage Disease Type II
Late-onset Glycogen Storage Disease type 2.
Glycogen Storage Disease Type II
Late-Onset Glycogen Storage Disease Type II (Pompe's Disease) with a Novel Mutation: A Malaysian Experience.
Glycogen Storage Disease Type II
Late-Onset Pompe Disease with Nemaline Bodies.
Glycogen Storage Disease Type II
Lentiviral gene therapy of murine hematopoietic stem cells ameliorates the Pompe disease phenotype.
Glycogen Storage Disease Type II
Letter to the Editors: Concerning "Divergent clinical outcomes of alpha-glucosidase enzyme replacement therapy in two siblings with infantile-onset Pompe disease treated in the symptomatic or pre-symptomatic state" by Takashi et al. and Letter to the Editors by Ortolano et al.
Glycogen Storage Disease Type II
Long-term benefit of enzyme replacement therapy with alglucosidase alfa in adults with Pompe disease: Prospective analysis from the French Pompe Registry.
Glycogen Storage Disease Type II
Long-term enzyme replacement therapy for pompe disease with recombinant human alpha-glucosidase derived from chinese hamster ovary cells.
Glycogen Storage Disease Type II
Long-term enzyme-replacement therapy (ERT) with alglucosidase alfa: Evolution of two siblings with juvenile late-onset Pompe disease.
Glycogen Storage Disease Type II
Long-term exposure to Myozyme results in a decrease of anti-drug antibodies in late-onset Pompe disease patients.
Glycogen Storage Disease Type II
Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk.
Glycogen Storage Disease Type II
Long-Term Observation of the Safety and Effectiveness of Enzyme Replacement Therapy in Japanese Patients with Pompe Disease: Results From the Post-marketing Surveillance.
Glycogen Storage Disease Type II
Looking for protein stabilizing drugs with thermal shift assay.
Glycogen Storage Disease Type II
Lymphocyte alpha-glucosidase in late-onset glycogenosis type II.
Glycogen Storage Disease Type II
Lysosomal glycogen storage mimicking the cytological picture of Pompe's disease as induced in rats by injection of an alpha-glucosidase inhibitor. I. Alterations in liver.
Glycogen Storage Disease Type II
Lysosomal storage diseases.
Glycogen Storage Disease Type II
Lysosomal storage of glycogen as a sequel of alpha-glucosidase inhibition by the absorbed deoxynojirimycin derivative emiglitate (BAYo1248). A drug-induced pattern of hepatic glycogen storage mimicking Pompe's disease (glycogenosis type II).
Glycogen Storage Disease Type II
Management of Confirmed Newborn-Screened Patients With Pompe Disease Across the Disease Spectrum.
Glycogen Storage Disease Type II
Molecular diagnosis of German patients with late-onset glycogen storage disease type II.
Glycogen Storage Disease Type II
Molecular Diagnosis of Pompe Disease in the Genomic Era: Correlation with Acid Alpha-Glucosidase Activity in Dried Blood Spots.
Glycogen Storage Disease Type II
Molecular study on the infantile form of Pompe disease in Chinese in Taiwan.
Glycogen Storage Disease Type II
Monitoring cardiac function by B-type natriuretic peptide (BNP) in patients with infantile Pompe's disease treated with recombinant alpha-glucosidase.
Glycogen Storage Disease Type II
Morphological changes in muscle tissue of patients with infantile Pompe's disease receiving enzyme replacement therapy.
Glycogen Storage Disease Type II
Multiple neutral maltase activities in normal and acid maltase-deficient human muscle.
Glycogen Storage Disease Type II
Muscle biopsy in Pompe disease.
Glycogen Storage Disease Type II
Muscle Proteomic Profile before and after Enzyme Replacement Therapy in Late-Onset Pompe Disease.
Glycogen Storage Disease Type II
Nephrotic syndrome complicating alpha-glucosidase replacement therapy for Pompe disease.
Glycogen Storage Disease Type II
New insights into therapeutic options for Pompe disease.
Glycogen Storage Disease Type II
New kind of cytoplasmic inclusions of plasma cells in acid maltase deficiency.
Glycogen Storage Disease Type II
New therapeutic approaches for Pompe disease: enzyme replacement therapy and beyond.
Glycogen Storage Disease Type II
Non-depleting anti-CD4 monoclonal antibody induces immune tolerance to ERT in a murine model of Pompe disease.
Glycogen Storage Disease Type II
Nosology of lysosomal glycogen storage diseases without in vitro acid maltase deficiency. Delineation of a neonatal form.
Glycogen Storage Disease Type II
Partial characterization of leucocyte alpha-glucosidase in late onset glycogenosis type II.
Glycogen Storage Disease Type II
Partial phenotypic correction and immune tolerance induction to enzyme replacement therapy after hematopoietic stem cell gene transfer of alpha-glucosidase in Pompe disease.
Glycogen Storage Disease Type II
Persistence of high sustained antibodies to enzyme replacement therapy despite extensive immunomodulatory therapy in an infant with Pompe disease: Need for agents to target antibody-secreting plasma cells.
Glycogen Storage Disease Type II
Pharmacological Enhancement of Mutated alpha-Glucosidase Activity in Fibroblasts from Patients with Pompe Disease.
Glycogen Storage Disease Type II
Phase I/II trial of adeno-associated virus-mediated alpha-glucosidase gene therapy to the diaphragm for chronic respiratory failure in Pompe disease: initial safety and ventilatory outcomes.
Glycogen Storage Disease Type II
Phenotype variations in early onset Pompe disease: diagnosis and treatment results with Myozyme.
Glycogen Storage Disease Type II
Pompe disease: a review of the current diagnosis and treatment recommendations in the era of enzyme replacement therapy.
Glycogen Storage Disease Type II
Pompe disease: pathogenesis, molecular genetics and diagnosis.
Glycogen Storage Disease Type II
Pompe's disease in Chinese and prenatal diagnosis by determination of alpha-glucosidase activity.
Glycogen Storage Disease Type II
Postmortem Findings and Clinical Correlates in Individuals with Infantile-Onset Pompe Disease.
Glycogen Storage Disease Type II
Prenatal diagnosis of Pompe disease by electron microscopy.
Glycogen Storage Disease Type II
Prenatal diagnosis of type II glycogenosis (Pompe's disease) using microchemical analyses.
Glycogen Storage Disease Type II
Prenatal exclusion of Pompe disease by electron microscopy.
Glycogen Storage Disease Type II
Preparation of monoclonal antibodies against acid alpha-D-glucosidase for study of Chinese glycogenosis type II patients.
Glycogen Storage Disease Type II
Progress in Enzyme Replacement Therapy in Glycogen Storage Disease Type II.
Glycogen Storage Disease Type II
Properties of the alpha-glucosidase from various human tissues in relation to glycogenosis type II (Pompe's disease).
Glycogen Storage Disease Type II
Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study.
Glycogen Storage Disease Type II
Quantitation of Alpha-Glucosidase Activity Using Fluorinated Carbohydrate Array and MALDI-TOF-MS.
Glycogen Storage Disease Type II
Quantitative whole-body magnetic resonance imaging in children with Pompe disease: Clinical tools to evaluate severity of muscle disease.
Glycogen Storage Disease Type II
Rapid diagnosis of late-onset Pompe disease by fluorometric assay of alpha-glucosidase activities in dried blood spots.
Glycogen Storage Disease Type II
Reappearance of embryonic neutral alpha-glucosidase isoenzyme in acid maltase-deficient muscle of Japanese quail.
Glycogen Storage Disease Type II
Recombinant human acid alpha-glucosidase (rhGAA) in adult patients with severe respiratory failure due to Pompe disease.
Glycogen Storage Disease Type II
Reevaluating the pathogenicity of the mutation c.1194 +5 G>A in GAA gene by functional analysis of RNA in a 61-year-old woman diagnosed with Pompe disease by muscle biopsy.
Glycogen Storage Disease Type II
Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers.
Glycogen Storage Disease Type II
Respiratory function during enzyme replacement therapy in late-onset Pompe disease: longitudinal course, prognostic factors, and the impact of time from diagnosis to treatment start.
Glycogen Storage Disease Type II
Safety and efficacy of alternative alglucosidase alfa regimens in Pompe disease.
Glycogen Storage Disease Type II
Safety of Intradiaphragmatic Delivery of Adeno-Associated Virus-Mediated Alpha-Glucosidase (rAAV1-CMV-hGAA) Gene Therapy in Children Affected by Pompe Disease.
Glycogen Storage Disease Type II
Screening for late-onset Pompe disease in western Denmark.
Glycogen Storage Disease Type II
Screening for Pompe disease using a rapid dried blood spot method: experience of a clinical diagnostic laboratory.
Glycogen Storage Disease Type II
Selective vacuolar myopathy with atrophy of type II fibers. Occurrence in a childhood case of acid maltase deficiency.
Glycogen Storage Disease Type II
Skeletal muscle pathology of infantile Pompe disease during long-term enzyme replacement therapy.
Glycogen Storage Disease Type II
Small intestinal glucoamylase deficiency and starch malabsorption: a newly recognized alpha-glucosidase deficiency in children.
Glycogen Storage Disease Type II
Stabilising normal and mis-sense variant alpha-glucosidase.
Glycogen Storage Disease Type II
STIG study: real-world data of long-term outcomes of adults with Pompe disease under enzyme replacement therapy with alglucosidase alfa.
Glycogen Storage Disease Type II
Structure of human lysosomal acid ?-glucosidase-a guide for the treatment of Pompe disease.
Glycogen Storage Disease Type II
Subcellular distribution of acid alpha-glucosidase in fibroblasts and of antigenically cross-reactive material in Pompe's disease fibroblasts.
Glycogen Storage Disease Type II
Successful Desensitisation in a Patient with CRIM-Positive Infantile-Onset Pompe Disease.
Glycogen Storage Disease Type II
Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease.
Glycogen Storage Disease Type II
Sudden deterioration in nonclassical infantile-onset Pompe disease responding to alglucosidase alfa infusion therapy: a case report.
Glycogen Storage Disease Type II
Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis.
Glycogen Storage Disease Type II
Sustained immune tolerance induction in enzyme replacement therapy-treated CRIM-negative patients with infantile Pompe disease.
Glycogen Storage Disease Type II
The bovine alpha-glucosidase gene: coding region, genomic structure, and mutations that cause bovine generalized glycogenosis.
Glycogen Storage Disease Type II
The change in the pH 4 and pH 6 forms of alpha-glucosidase in cultured amniotic fluid cells and its implication in prenatal diagnosis of Pompe's disease.
Glycogen Storage Disease Type II
The electrophoretic pattern and activities of acid and neutral maltase of cultivated fibroblasts and amniotic fluid cells from controls and patients with the variant of glycogen storage disease type II (Pompe's disease).
Glycogen Storage Disease Type II
The emerging phenotype of long-term survivors with infantile Pompe disease.
Glycogen Storage Disease Type II
The endocrine glands in Pompe's disease. Report of two cases.
Glycogen Storage Disease Type II
The impact of Pompe disease on smooth muscle: a review.
Glycogen Storage Disease Type II
The new era of Pompe disease: advances in the detection, understanding of the phenotypic spectrum, pathophysiology, and management.
Glycogen Storage Disease Type II
The Pharmacological Chaperone AT2220 Increases Recombinant Human Acid ?-Glucosidase Uptake and Glycogen Reduction in a Mouse Model of Pompe Disease.
Glycogen Storage Disease Type II
The spectrum of myotonic and myopathic disorders in a pediatric electromyography laboratory over 12 years.
Glycogen Storage Disease Type II
The use of acarbose inhibition in the measurement of acid alpha-glucosidase activity in blood lymphocytes for the diagnosis of Pompe disease.
Glycogen Storage Disease Type II
Therapeutic approaches in glycogen storage disease type II/Pompe Disease.
Glycogen Storage Disease Type II
Three patients with glycogen storage disease type II and the mutational spectrum of GAA in Korean patients.
Glycogen Storage Disease Type II
Tissue alpha-glucosidase activity and glycogen content in patients with generalized glycogenosis.
Glycogen Storage Disease Type II
Treatment of acid maltase deficiency with a diet high in branched-chain amino acids.
Glycogen Storage Disease Type II
Tris discriminates between the different alpha-glucosidase activities from extracts of human neutrophils.
Glycogen Storage Disease Type II
Two alpha-glucosidases in cultured amniotic fluid cells and their differentiation in the prenatal diagnosis of Pompe's disease.
Glycogen Storage Disease Type II
Two cases of Pompe's disease: case report and review of literature.
Glycogen Storage Disease Type II
Two extremes of the clinical spectrum of glycogen storage disease type II in one family: a matter of genotype.
Glycogen Storage Disease Type II
Two successfully completed pregnancies in adult onset Pompe disease, under continued treatment with alglucosidase alfa.
Glycogen Storage Disease Type II
Urinary alpha-glucosidase analysis for the detection of the adult form of Pompe's disease.
Glycogen Storage Disease Type II
Use of immobilized antibodies in investigating acid alpha-glucosidase in urine in relation to Pompe's disease.
Glycogen Storage Disease Type II
Using human Pompe disease-induced pluripotent stem cell-derived neural cells to identify compounds with therapeutic potential.
Glycogen Storage Disease Type II
White blood cells and the diagnosis of alpha-glucosidase deficiency.
Glycogen Storage Disease Type II
Zonal differences of alpha-glucosidases in human kidney: studies in controls and in patients with glycogenosis type II.
Glycogen Storage Disease Type II
[Adult form of Pompe disease]
Glycogen Storage Disease Type II
[Biochemical diagnosis of glycogenosis type II (acid maltase deficiency) (author's transl)]
Glycogen Storage Disease Type II
[Clinical, preclinical and prenatal diagnosis of congenital sphingolipidoses by determining lysosomal hydrolases (author's transl)]
Glycogen Storage Disease Type II
[Enzyme replacement therapies for lysosomal storage disorders.]
Glycogen Storage Disease Type II
[Enzyme replacement therapy in Pompe's disease]
Glycogen Storage Disease Type II
[Guidelines for monitoring late-onset Pompe disease.Sociedad Española de Medicina Interna (SEMI), Sociedad Española de Neurología (SEN) y Sociedad Española de Neumología y CirugíaTorácica (SEPAR)].
Glycogen Storage Disease Type II
[Late infantile form of Pompe's disease. Deficiency of alpha-1,4-glucosidase (acid maltase)]
Glycogen Storage Disease Type II
[Pompe and his disease].
Glycogen Storage Disease Type II
[Tests for the detection of inborn errors of metabolism--urinary alpha-glucosidase analysis for the detection of glycogen storage disease type II (author's transl)]
Glycogen Storage Disease Type III
Alglucosidase alfa enzyme replacement therapy as a therapeutic approach for glycogen storage disease type III.
Glycogen Storage Disease Type IV
Acid maltase deficiency and related myopathies.
Glycogen Storage Disease Type IV
Alglucosidase alfa treatment alleviates liver disease in a mouse model of glycogen storage disease type IV.
Glycosuria
Effect of the alpha-glucosidase inhibitor Bay-O-1248 on the metabolic response of nondiabetic and diabetic rats to a high-carbohydrate diet.
Glycosuria
Reversal of abnormal retinal hemodynamics in diabetic rats by acarbose, an alpha-glucosidase inhibitor.
Heart Block
Complete heart block with myocardial membrane-bound glycogen and normal peripheral alpha-glucosidase activity.
Heart Failure
Alpha-glucosidase inhibitors: new therapeutic agents for chronic heart failure.
Heart Failure
Control of plasma glucose with alpha-glucosidase inhibitor attenuates oxidative stress and slows the progression of heart failure in mice.
Heart Failure
Correction: The effect of luseogliflozin and alpha-glucosidase inhibitor on heart failure with preserved ejection fraction in diabetic patients: rationale and design of the MUSCAT-HF randomised controlled trial.
Heart Failure
Risk of hospitalization for heart failure associated with thiazolidinedione therapy: a medicaid claims-based case-control study.
Heart Failure
The effect of luseogliflozin and alpha-glucosidase inhibitor on heart failure with preserved ejection fraction in diabetic patients: rationale and design of the MUSCAT-HF randomised controlled trial.
Hemorrhagic Stroke
[The association between plasma neurotransmitters levels and depression in acute hemorrhagic stroke].
Hepatitis
Activity of alpha-1,4-glucosidase in extrahepatic cholestasis and acute viral hepatitis.
Hepatitis
Serum beta-N-acetylglucosaminidase, beta-D-glucosidase, alpha-D-glucosidase, beta-D-fucosidase, alpha-L-fucosidase and beta-D-galactosidase levels in acute viral hepatitis, pancreatitis, myocardial infarction and breast cancer.
Hepatitis B
Aberrant trafficking of hepatitis B virus glycoproteins in cells in which N-glycan processing is inhibited.
Hepatitis B
Adding to the hepatitis B virus treatment arsenal: alpha-glucosidase inhibitor derivatives.
Hepatitis B
alpha-Glucosidase inhibitors have a prolonged antiviral effect against hepatitis B virus through the sustained inhibition of the large and middle envelope glycoproteins.
Hepatitis B
Treatment of hepatitis B virus-infected cells with alpha-glucosidase inhibitors results in production of virions with altered molecular composition and infectivity.
Hepatitis C
Reduction of the infectivity of hepatitis C virus pseudoparticles by incorporation of misfolded glycoproteins induced by glucosidase inhibitors.
Herpes Simplex
The effect of oral treatment with 6-O-butanoyl castanospermine (MDL 28,574) in the murine zosteriform model of HSV-1 infection.
Herpes Zoster
Relationship between semen characteristics, alpha-glucosidase and the capacity of spermatozoa to bind to the human zona pellucida.
HIV Infections
A novel lectin from Pseudostellaria heterophylla roots with sequence simularity to Kunitz-type soybean trypsin inhibitor.
HIV Infections
Hypogin, a novel antifungal peptide from peanuts with sequence similarity to peanut allergen.
HIV Infections
Structurally dissimilar proteins with antiviral and antifungal potency from cowpea (Vigna unguiculata) seeds.
Huntington Disease
Loss of endoplasmic reticulum-associated enzymes in affected brain regions in Huntington's disease and Alzheimer-type dementia.
Hydronephrosis
[Neutral alpha-glucosidase activity in the urine in congenital hydronephrosis in children]
Hypercholesterolemia
Anti-hyperglycemic and anti-hyperlipidemic effects of guava leaf extract.
Hypercholesterolemia
Blood glucose-lowering activity of colestimide in patients with type 2 diabetes and hypercholesterolemia: a case-control study comparing colestimide with acarbose.
Hyperglycemia
A pilot study of the efficacy of miglitol and sitagliptin for type 2diabetes with a continuous glucose monitoring system and incretin-related markers.
Hyperglycemia
A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44)
Hyperglycemia
A review of alpha-glucosidase inhibitors from plants as potential candidates for the treatment of type-2 diabetes.
Hyperglycemia
A series of cinnamic acid derivatives and their inhibitory activity on intestinal alpha-glucosidase.
Hyperglycemia
Acarbose is a promising therapeutic strategy for the treatment of patients with nonalcoholic steatohepatitis (NASH).
Hyperglycemia
Acarbose partially prevents the development of diabetes mellitus by multiple low-dose streptozotocin administration.
Hyperglycemia
Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.
Hyperglycemia
Acarbose treatments improve arterial stiffness in patients with type 2 diabetes mellitus.
Hyperglycemia
Acarbose, an alpha-glucosidase inhibitor, improves insulin resistance in fructose-fed rats.
Hyperglycemia
Alleviating the Hydrolysis of Carbohydrates, Tangzhiqing (TZQ) Decreased the Postprandial Glycemia in Healthy Volunteers: An Eight-Period Crossover Study.
Hyperglycemia
alpha-Glucosidase inhibition improves postprandial hyperglycemia and decreases insulin requirements in insulin-dependent diabetes mellitus.
Hyperglycemia
alpha-Glucosidase inhibitors prevent diet-induced increases in intestinal sugar transport in diabetic mice.
Hyperglycemia
Alpha-glucosidase inhibitory activity of a 70% methanol extract from ezoishige (Pelvetia babingtonii de Toni) and its effect on the elevation of blood glucose level in rats.
Hyperglycemia
Altered expression of muscle glucose transporter GLUT-4 in diabetic fatty Zucker rats (ZDF/Drt-fa).
Hyperglycemia
An alpha-glucosidase inhibitor, AO-128, retards carbohydrate absorption in rats and humans.
Hyperglycemia
Anti-diabetic and anti-hypertensive potential of sprouted and solid-state bioprocessed soybean.
Hyperglycemia
Anti-hyperglycemic and anti-hyperlipidemic effects of guava leaf extract.
Hyperglycemia
Antioxidant rich grape pomace extract suppresses postprandial hyperglycemia in diabetic mice by specifically inhibiting alpha-glucosidase.
Hyperglycemia
Biological interaction of newly synthesized astaxanthin-s-allyl cysteine biconjugate with Saccharomyces cerevisiae and mammalian ?-glucosidase: In vitro kinetics and in silico docking analysis.
Hyperglycemia
Changes in alpha-glucosidase activities along the jejunal-ileal axis of normal rats by the alpha-glucosidase inhibitor miglitol.
Hyperglycemia
Clinical utility of acarbose, an alpha-glucosidase inhibitor in cardiometabolic disorders.
Hyperglycemia
Comparison of efficacies of a dipeptidyl peptidase IV inhibitor and alpha-glucosidase inhibitors in oral carbohydrate and meal tolerance tests and the effects of their combination in mice.
Hyperglycemia
Control of post-prandial hyperglycemia--an essential part of good diabetes treatment and prevention of cardiovascular complications.
Hyperglycemia
Critical evaluation of the role of acarbose in the treatment of diabetes: patient considerations.
Hyperglycemia
Current treatment approaches to type 2 diabetes mellitus: successes and shortcomings.
Hyperglycemia
Dieckol isolated from Ecklonia cava inhibits alpha-glucosidase and alpha-amylase in vitro and alleviates postprandial hyperglycemia in streptozotocin-induced diabetic mice.
Hyperglycemia
Diphlorethohydroxycarmalol isolated from Ishige okamurae, a brown algae, a potent alpha-glucosidase and alpha-amylase inhibitor, alleviates postprandial hyperglycemia in diabetic mice.
Hyperglycemia
Effect of lipid extracts of Nigella sativa L. seeds on the liver ATP reduction and alpha-glucosidase inhibition.
Hyperglycemia
Effect of two alpha-glucosidase inhibitors, voglibose and acarbose, on postprandial hyperglycemia correlates with subjective abdominal symptoms.
Hyperglycemia
Effects of diabetes and hyperglycemia on disaccharidase activities in the rat.
Hyperglycemia
Efficacy and safety of miglitol- or repaglinide-based combination therapy with alogliptin in drug-naïve patients with type 2 diabetes: An open-label, single-center, parallel, randomized control pilot study.
Hyperglycemia
Elevated serum levels of interleukin-18 in patients with overt diabetic nephropathy: effects of miglitol.
Hyperglycemia
Enzymes inhibitors from natural sources with antidiabetic activity: A review.
Hyperglycemia
Evaluation of antihyperglycemia and antihypertension potential of native Peruvian fruits using in vitro models.
Hyperglycemia
Experimental treatment of complications in alloxan diabetic rats with alpha-glucosidase inhibitor from the Chinese medicinal herb ramulus mori.
Hyperglycemia
Extracts of Momordica charantia suppress postprandial hyperglycemia in rats.
Hyperglycemia
Functionality of bioactive compounds in Brazilian strawberry (Fragaria x ananassa Duch.) cultivars: evaluation of hyperglycemia and hypertension potential using in vitro models.
Hyperglycemia
In Vitro Alpha-Amylase and Alpha-Glucosidase Inhibitory Activity and In Vivo Antidiabetic Activity of Withania frutescens L. Foliar Extract.
Hyperglycemia
In vitro inhibitory effects of plant-based foods and their combinations on intestinal ¿-glucosidase and pancreatic ¿-amylase.
Hyperglycemia
Inhibition of alpha-glucosidase and amylase by luteolin, a flavonoid.
Hyperglycemia
Inhibition of alpha-glucosidase by aqueous extracts of some potent antidiabetic medicinal herbs.
Hyperglycemia
Inhibition of glucose absorption in the rat jejunum: a novel action of alpha-D-glucosidase inhibitors.
Hyperglycemia
Inhibition of intestinal alpha-glucosidase and postprandial hyperglycemia by N-substituted moranoline derivatives.
Hyperglycemia
Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
Hyperglycemia
Inhibitory activity of Euonymus alatus against alpha-glucosidase in vitro and in vivo.
Hyperglycemia
Inhibitory effect of Azadirachta indica A. juss leaf extract on the activities of alpha-amylase and alpha-glucosidase.
Hyperglycemia
Inhibitory effect of koji Aspergillus terreus on alpha-glucosidase activity and postprandial hyperglycemia.
Hyperglycemia
Inhibitory effect of methanol extract of Rosa damascena Mill. flowers on alpha-glucosidase activity and postprandial hyperglycemia in normal and diabetic rats.
Hyperglycemia
Inhibitory effect of pine extract on alpha-glucosidase activity and postprandial hyperglycemia.
Hyperglycemia
Inhibitory effects of hyssop (Hyssopus officinalis) extracts on intestinal alpha-glucosidase activity and postprandial hyperglycemia.
Hyperglycemia
Insulin releasing and alpha-glucosidase inhibitory activity of ethyl acetate fraction of Acorus calamus in vitro and in vivo.
Hyperglycemia
Intestinal alpha-glucosidase inhibitory activity and toxicological evaluation of Nymphaea stellata flowers extract.
Hyperglycemia
Miglitol improves postprandial endothelial dysfunction in patients with acute coronary syndrome and new-onset postprandial hyperglycemia.
Hyperglycemia
Miglitol prevents diet-induced obesity by stimulating brown adipose tissue and energy expenditure independent of preventing the digestion of carbohydrates.
Hyperglycemia
Miglitol protects against age-dependent weight gain in mice: A potential role of increased UCP1 content in brown adipose tissue.
Hyperglycemia
Miglitol suppresses the postprandial increase in interleukin 6 and enhances active glucagon-like peptide 1 secretion in viscerally obese subjects.
Hyperglycemia
New developments in type 2 diabetes mellitus: combination therapy with a thiazolidinedione.
Hyperglycemia
Plasma glycohydrolase levels in patients with type 1 diabetes at onset and in subjects undergoing an intravenous glucose tolerance test.
Hyperglycemia
Postprandial hyperglycemia: implications for practice.
Hyperglycemia
Potent alpha-glucosidase inhibitors purified from the red alga Grateloupia elliptica.
Hyperglycemia
Punica granatum flower extract, a potent alpha-glucosidase inhibitor, improves postprandial hyperglycemia in Zucker diabetic fatty rats.
Hyperglycemia
Reduction of postprandial hyperglycemia in patients with type 2 diabetes reduces NF-kappaB activation in PBMCs.
Hyperglycemia
Relationship between gastric emptying and an alpha-glucosidase inhibitor effect on postprandial hyperglycemia in NIDDM patients.
Hyperglycemia
Repetitive postprandial hyperglycemia increases cardiac ischemia/reperfusion injury: prevention by the alpha-glucosidase inhibitor acarbose.
Hyperglycemia
Salacia oblonga improves cardiac fibrosis and inhibits postprandial hyperglycemia in obese Zucker rats.
Hyperglycemia
Screening alpha-glucosidase and alpha-amylase inhibitors from natural compounds by molecular docking in silico.
Hyperglycemia
Single administration of alpha-glucosidase inhibitors on endothelial function and incretin secretion in diabetic patients with coronary artery disease - Juntendo University trial: effects of miglitol on endothelial vascular reactivity in type 2 diabetic patients with coronary heart disease (J-MACH) -.
Hyperglycemia
Synthesis and alpha-glucosidase-inhibiting activity of a new alpha-glucosidase inhibitor, 4-O-alpha-D-glucopyranosylmoranoline and its N-substituted derivatives.
Hyperglycemia
The alpha-glucosidase inhibitor acarbose prevents obesity and simple steatosis in sequestosome 1/A170/p62 deficient mice.
Hyperglycemia
The alpha-glucosidase inhibitor miglitol affects bile acid metabolism and ameliorates obesity and insulin resistance in diabetic mice.
Hyperglycemia
The alpha-glucosidase inhibitor miglitol decreases glucose fluctuations and gene expression of inflammatory cytokines induced by hyperglycemia in peripheral leukocytes.
Hyperglycemia
Treating dual defects in diabetes: insulin resistance and insulin secretion.
Hyperglycemia
Treatment of type 2 diabetes mellitus in children and adolescents.
Hyperglycemia
Treatment with acarbose may improve endothelial dysfunction in streptozotocin-induced diabetic rats.
Hyperglycemia
Voglibose (Basen, AO-128), one of the most important alpha-glucosidase inhibitors.
Hyperglycemia
Voglibose potentiates the hepatotoxicity of carbon tetrachloride and acetaminophen by inducing CYP2E1 in rats.
Hyperglycemia
Who should benefit from the use of alpha-glucosidase inhibitors?
Hyperglycemia
[Current evidence on the early intervention of diabetes]
Hyperglycemia
[Development of alpha-glucosidase inhibitor from medicinal herbs]
Hyperglycemia
[Exploring an optimal approach to the use of oral hypoglycemic agents based on CGM results: implications for combination therapy with oral hypoglycemic agents].
Hyperglycemia
[Hypoglycemia in the diabetes treatment - risk minimization with dipeptidyl peptidase-4 inhibitors].
Hyperglycemia
[Occurrence of ileus after voglibose treatment in an elderly diabetic patient with gait disturbance caused by cerebral hemorrhage]
Hyperglycemia
[Study on the inhibition of alpha-glucosidase by soyasaponins]
Hyperglycemia
[The clinical significance of early intervention for impaired glucose tolerance]
Hyperglycemia
[Valibose, an alpha-glucosidase inhibitor, ameliorates the metabolic disorder of glucose and lipids and the nephropathy in streptozotocin-induced diabetic rats].
Hyperinsulinism
An alpha-glucosidase inhibitor, AO-128, retards carbohydrate absorption in rats and humans.
Hyperinsulinism
Anti-hyperglycemic and anti-hyperlipidemic effects of guava leaf extract.
Hyperinsulinism
Cardiovascular disease in the JCR:LA-cp rat.
Hyperinsulinism
Effects of acarbose in beta-thalassaemia major patients with normal glucose tolerance and hyperinsulinism.
Hyperinsulinism
Hypokalemic periodic paralysis in a patient with acquired growth hormone deficiency.
Hyperinsulinism
Voglibose (Basen, AO-128), one of the most important alpha-glucosidase inhibitors.
Hyperlipidemias
Inhibitory effects of estrogens on digestive enzymes, insulin deficiency, and pancreas toxicity in diabetic rats.
Hyperlipoproteinemia Type II
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY.
Hyperlipoproteinemia Type II
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2020 EXECUTIVE SUMMARY.
Hypertension
Acarbose is a promising therapeutic strategy for the treatment of patients with nonalcoholic steatohepatitis (NASH).
Hypertension
Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.
Hypertension
Alpha-glucosidase inhibitors 2012 - cardiovascular considerations and trial evaluation.
Hypertension
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY.
Hypertension
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY.
Hypertension
Evaluation of antihyperglycemia and antihypertension potential of native Peruvian fruits using in vitro models.
Hypertension
Evaluation of urinary enzyme patterns in patients with kidney diseases and primary benign hypertension.
Hypertension
Functionality of bioactive compounds in Brazilian strawberry (Fragaria x ananassa Duch.) cultivars: evaluation of hyperglycemia and hypertension potential using in vitro models.
Hypertension
Modulation of circulating vasoactive peptides and extracellular matrix proteins are two novel mechanisms in the cardioprotective action of acarbose.
Hypertension
Phenolic-linked variation in strawberry cultivars for potential dietary management of hyperglycemia and related complications of hypertension.
Hypertension
Pioglitazone produces rapid and persistent reduction of vascular inflammation in patients with hypertension and type 2 diabetes mellitus who are receiving angiotensin II receptor blockers.
Hypertension
Potential of Ginkgo biloba L. leaves in the management of hyperglycemia and hypertension using in vitro models.
Hypertension
Systemic medications and cortical cataract: the Singapore Epidemiology of Eye Diseases Study.
Hyperthyroidism
Serum lysosomal acid hydrolase activities in Graves' disease.
Hypertriglyceridemia
Reduction of carbohydrate-induced hypertriglyceridemia in (fa,fa) "Zucker" rats by the alpha-glucosidase inhibitor acarbose (BAY g 5421).
Hypervitaminosis A
Effect of hypervitaminosis A on intestinal digestive & absorptive functions in rat.
Hypoglycemia
A new approach to the treatment of nocturnal hypoglycemia using alpha-glucosidase inhibition.
Hypoglycemia
Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients.
Hypoglycemia
Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice.
Hypoglycemia
Comparison of antidiabetic drugs added to sulfonylurea monotherapy in patients with type 2 diabetes mellitus: A network meta-analysis.
Hypoglycemia
Concurrent Therapy with a Low-carbohydrate Diet and Miglitol Remarkably Improved the Postprandial Blood Glucose and Insulin Levels in a Patient with Reactive Hypoglycemia due to Late Dumping Syndrome.
Hypoglycemia
Emergence of promising novel DPP-4 inhibitory heterocycles as anti-diabetic agents: A review.
Hypoglycemia
Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting.
Hypoglycemia
Nateglinide is Effective for Diabetes Mellitus with Reactive Hypoglycemia in a Child with a Compound Heterozygous ABCC8 Mutation.
Hypoglycemia
Pioglitazone prevents reactive hypoglycemia in impaired glucose tolerance.
Hypoglycemia
Postprandial Reactive Hypoglycemia Treated with a Low-dose Alpha-glucosidase Inhibitor: Voglibose May Suppress Oxidative Stress and Prevent Endothelial Dysfunction.
Hypoglycemia
Safety, tolerability and efficacy of lixisenatide in combination with oral antidiabetic treatment in Japanese patients with type 2 diabetes: An open-label, multicenter study.
Hypoglycemia
Treatment with alpha-glucosidase inhibitor for severe reactive hypoglycemia: a case report.
Hypoglycemia
Use of the alpha glucosidase inhibitor acarbose in patients with 'Middleton syndrome': normal gastric anatomy but with accelerated gastric emptying causing postprandial reactive hypoglycemia and diarrhea.
Hypoglycemia
[Alpha-glucosidase inhibitors: a new therapeutic approach in diabetes and functional hypoglycemia]
Hypoglycemia
[Evaluation of the association between the use of oral anti-hyperglycemic agents and hypoglycemia in Japan by data mining of the Japanese Adverse Drug Event Report (JADER) database].
Hypotension
Acarbose, an alpha-glucosidase inhibitor, attenuates postprandial hypotension in autonomic failure.
Hypotension
[A case of hemodynamic brain infarction with postprandial hypotension]
Hypothyroidism
Relative importance of corticosterone and thyroxine in the postnatal development of sucrase and maltase in rat small intestine.
Ileus
Ileus after administration of cold remedy in an elderly diabetic patient treated with acarbose.
Infections
A high-throughput assay using dengue-1 virus-like particles for drug discovery.
Infections
Antiviral effect of {alpha}-glucosidase inhibitors on viral morphogenesis and binding properties of hepatitis C virus-like particles.
Infections
Astrovirus infection in hatchling turkeys: alterations in intestinal maltase activity.
Infections
Biochemical analysis of jejunal brush border membrane of golden hamster: pathogenic modulations due to ancylostomiasis.
Infections
Castanospermine, a potent inhibitor of dengue virus infection in vitro and in vivo.
Infections
Changes in the intestinal enzyme activity of lambs during chronic infection with Trichostrongylus vitrinus.
Infections
Comparative development of Brugia pahangi and variation in acid hydrolase enzyme titers in.
Infections
Content of saccharides and activity of alpha-glycosidases in Galleria mellonella larvae infected with entomopathogenic nematodes Heterorhabditis zealandica.
Infections
Diagnostic potential of urinary enzymes and beta 2-microglobulin in acute urinary tract infection.
Infections
Disaccharidase activity in male and female C57BL/6 mice infected with Giardia muris.
Infections
Disaccharidase activity in the small intestine of susceptible and resistant mice after primary and challenge infections with Giardia muris.
Infections
Disaccharidase deficiencies in Mongolian gerbils (Meriones unguiculatus) protected against Giardia lamblia.
Infections
Impact of infection on the secretory capacity of the male accessory glands.
Infections
Intestinal enzyme profiles in normal and rotavirus-infected mice.
Infections
[Automatic detection and clinical application of semen biochemical markers].
Infections
[Study of lysosomal enzymes in chick embryo fibroblasts infected with microorganisms of family Halprowiaceae (Chlamydiaceae)]
Infections
[Ureaplasma urealyticum infection in the genital tract reduces seminal quality in infertile men]
Infertility
Approaches to post-testicular contraception.
Infertility
Correlation between neutral alpha-glucosidase activity and sperm DNA fragmentation.
Infertility
Epididymal markers in human infertility.
Infertility
New discriminatory level for glucosidase activity to diagnose epididymal obstruction or dysfunction.
Infertility
Origin of maltase and variations in infertile men.
Infertility
Seminal alpha-glucosidase activity as a marker of epididymal pathology in nonazoospermic men consulting for infertility.
Infertility
The value of semen characteristics and tests of sperm function in selecting couples for intra-uterine insemination.
Infertility
Why do we determine alpha-glucosidase activity in human semen during infertility work-up?
Infertility
[Changes in the enzyme level of the sperm of men with infertility]
Infertility, Male
Seminal plasma alpha-glucosidase activity and male infertility.
Infertility, Male
Seminal Plasma Analysis of Oxidative Stress in Different Genitourinary Topographical Regions Involved in Reproductive Tract Disorders Associated with Genital Heat Stress.
Inflammatory Bowel Diseases
Subcellular fractionation of rectal biopsy homogenates from patients with inflammatory bowel disease.
Inflammatory Bowel Diseases
The role of probiotic cultures in the control of gastrointestinal health.
Influenza, Human
Gateways to clinical trials.
Influenza, Human
Inhibition of mouse liver sialidase by plant flavonoids.
Influenza, Human
On the role of oligosaccharide trimming in the maturation of Sindbis and influenza virus.
Insulin Resistance
A rational approach to drug therapy of type 2 diabetes mellitus.
Insulin Resistance
Acarbose treatment increases serum total adiponectin levels in patients with type 2 diabetes.
Insulin Resistance
Acarbose, an alpha-glucosidase inhibitor, improves insulin resistance in fructose-fed rats.
Insulin Resistance
Current therapies and emerging targets for the treatment of diabetes.
Insulin Resistance
Does suppression of postprandial blood glucose excursions by the alpha-glucosidase inhibitor miglitol improve insulin sensitivity in diet-treated type II diabetic patients?
Insulin Resistance
Effect of acarbose on insulin sensitivity in elderly patients with diabetes.
Insulin Resistance
Effect of pioglitazone on muscle sympathetic nerve activity in type 2 diabetes mellitus with alpha-glucosidase inhibitor.
Insulin Resistance
Effects of 8-wk alpha-glucosidase inhibition on metabolic control, C-peptide secretion, hepatic glucose output, and peripheral insulin sensitivity in poorly controlled type II diabetic patients.
Insulin Resistance
Effects of voglibose on glycemic excursions, insulin secretion, and insulin sensitivity in non-insulin-treated NIDDM patients.
Insulin Resistance
How should postprandial glycemia be treated?
Insulin Resistance
Hypoglycemic and hypolipidemic effects of samnamul (shoot of Aruncus dioicus var. kamtschaticus Hara) in mice fed a high-fat/high-sucrose diet.
Insulin Resistance
Hypokalemic periodic paralysis in a patient with acquired growth hormone deficiency.
Insulin Resistance
Improvement of insulin sensitivity and dyslipidemia with a new alpha-glucosidase inhibitor, voglibose, in nondiabetic hyperinsulinemic subjects.
Insulin Resistance
Oral antidiabetic agents in type 2 diabetes.
Insulin Resistance
The alpha-glucosidase inhibitor acarbose prevents obesity and simple steatosis in sequestosome 1/A170/p62 deficient mice.
Insulin Resistance
The alpha-glucosidase inhibitor miglitol affects bile acid metabolism and ameliorates obesity and insulin resistance in diabetic mice.
Insulin Resistance
The alpha-glucosidase inhibitor miglitol increases hepatic CYP7A1 activity in association with altered short-chain fatty acid production in the gut of obese diabetic mice.
Insulin Resistance
The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance.
Insulin Resistance
The pathophysiologic basis of efficacy and clinical experience with the new oral antidiabetic agents.
Insulin Resistance
Treatment of type 2 diabetes mellitus in children and adolescents.
Insulin Resistance
Troglitazone combination therapy in obese type 2 diabetic patients poorly controlled with alpha-glucosidase inhibitors.
Insulin Resistance
[Management of diabetes during corticosteroid therapy]
Insulin Resistance
[Molecular targets for new drug discovery to treat type 2 diabetes and obesity]
Insulin Resistance
[Total care for patients with metabolic syndrome]
Insulinoma
A case of insulinoma following total gastrectomy--effects of an alpha-glucosidase inhibitor on suppressing GIP and GLP-1 elevations.
Intestinal Obstruction
Acute intestinal infarction or obstruction: search for better laboratory tests in an animal model.
Intestinal Obstruction
Prenatal detection of intestinal obstructions, aneuploidy syndromes, and cystic fibrosis by microvillar enzyme assays (disaccharidases, alkaline phosphatase, and glutamyltransferase) in amniotic fluid.
Intestinal Pseudo-Obstruction
Paralytic ileus accompanied by pneumatosis cystoides intestinalis after acarbose treatment in an elderly diabetic patient with a history of heavy intake of maltitol.
Intestinal Volvulus
Correction to: Pneumatosis cystoides intestinalis induced by the alpha-glucosidase inhibitor complicated from sigmoid volvulus in a diabetic patient.
Intestinal Volvulus
Pneumatosis cystoides intestinalis induced by the alpha-glucosidase inhibitor complicated from sigmoid volvulus in a diabetic patient.
Intracranial Aneurysm
Alpha-glucosidase deficiency and basilar artery aneurysm: report of a sibship.
Irritable Bowel Syndrome
The role of probiotic cultures in the control of gastrointestinal health.
Kidney Diseases
Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice.
Kidney Diseases
[Neutral alpha glucosidase in human urine as a marker of kidney impairment]
Kidney Diseases
[Soluble and membrane-bound forms of neutral alpha-glucosidase in human urine in normal conditions and in kidney diseases]
Kidney Diseases
[Urinary excretion of alpha-glucosidase in various kidney diseases]
Kidney Neoplasms
The Antidiabetic Agent Acarbose Improves Anti-PD-1 and Rapamycin Efficacy in Preclinical Renal Cancer.
Kwashiorkor
Moderate and severe protein energy malnutrition in childhood: effects on jejunal mucosal morphology and disaccharidase activities.
lactase deficiency
Disaccharidase activity in children undergoing esophagogastroduodenoscopy: A systematic review.
lactase deficiency
Mucosal abnormalities in microsporidiosis.
lactase deficiency
Patients with functional bowel disorder have disaccharidase deficiency: A single-center study from Russia.
lactase deficiency
Selective alteration of brush-border hydrolases in intestinal diseases in childhood.
lactase deficiency
[Disaccharidase deficiency and functional bowel diseases].
Lactose Intolerance
Evaluation of differential disaccharide excretion in urine for non-invasive investigation of altered intestinal disaccharidase activity caused by alpha-glucosidase inhibition, primary hypolactasia, and coeliac disease.
Lactose Intolerance
The role of probiotic cultures in the control of gastrointestinal health.
Lactose Intolerance
[Current problems of lactase deficiency]
Leprosy, Lepromatous
Urinary excretion of renal brush-border enzymes in lepromatous leprosy--a preliminary investigation.
Leukemia
Neutral maltase: the first human B-cell enzymatic marker reflecting terminal differentiation of mature B cells into plasma cells.
Leukemia
Serum and host liver activities of glycosidases and sialyltransferases in animals bearing transplantable tumors.
Leukemia, Lymphoid
Neutral maltase: the first human B-cell enzymatic marker reflecting terminal differentiation of mature B cells into plasma cells.
Leukodystrophy, Metachromatic
[Clinical, preclinical and prenatal diagnosis of congenital sphingolipidoses by determining lysosomal hydrolases (author's transl)]
Liver Cirrhosis
Effects of a late evening snack combined with alpha-glucosidase inhibitor on liver cirrhosis.
Liver Cirrhosis
Evaluation of renal tubular damage in liver cirrhosis by urinary enzymes and beta-2-microglobulin excretions.
Liver Cirrhosis
[Non-insulin-dependent diabetes mellitus associated with nonalcoholic liver cirrhosis: an evaluation of treatment with the intestinal alpha-glucosidase inhibitor acarbose]
Liver Diseases
Alglucosidase alfa treatment alleviates liver disease in a mouse model of glycogen storage disease type IV.
Liver Diseases
alpha-Glucosidase inhibitor acarbose and sequestome 1/A170/p62 deficient mice: A promising therapy and unique model for non-alcoholic fatty liver disease.
Liver Diseases
Hypophosphatemia and renal tubular dysfunction in alcoholics. Are they related to liver function impairment?
Liver Diseases
Safe and effective treatment of diabetes mellitus associated with chronic liver diseases with an alpha-glucosidase inhibitor, acarbose.
Liver Diseases
Thiazolidinediones, alpha-glucosidase inhibitors, meglitinides, sulfonylureas, and hepatocellular carcinoma risk: A meta-analysis.
Lung Diseases
Serum neutral alpha-D-glucosidase from patients with cystic fibrosis and chronic pulmonary disease.
Lung Diseases, Interstitial
Pneumatosis cystoides intestinalis after alpha-glucosidase inhibitor treatment in a patient with interstitial pneumonitis.
Lupus Vasculitis, Central Nervous System
Pneumatosis cystoides intestinalis in neuropsychiatric systemic lupus erythematosus with diabetes mellitus: case report and literature review.
Lymphoma
alpha-Glucosidase II-deficient cells use endo alpha-mannosidase as a bypass route for N-linked oligosaccharide processing.
Lymphoma
Identity of neutral alpha-glucosidase AB and the glycoprotein processing enzyme glucosidase II. Biochemical and genetic studies.
Lymphoma
Transient expression of human neutral alpha-glucosidase AB (glucosidase II) in enzyme-deficient mouse lymphoma cells.
Lysosomal Storage Diseases
Acid alpha-glucosidase deficiency (glycogenosis type II, Pompe disease).
Malabsorption Syndromes
[L-alanyl-L-proline-dipeptidase and glycyl-L-valine-depeptidase in malabsorption syndrome]
Malnutrition
Contribution of villous atrophy to reduced intestinal maltase in infants with malnutrition.
Malnutrition
Effect of pre- & post-weaning protein energy malnutrition on intestinal sucrase & maltase in rats.
Malnutrition
Effect of prenatal exposure to ethanol on intestinal development of rat fetuses.
Malnutrition
Interaction of malnutrition and difluoromethylornithine-induced intestinal mucosal damage: degree of severity and subsequent recovery.
Malnutrition
Jejunal disaccharidases in protein energy malnutrition and recovery.
Malnutrition
Moderate and severe protein energy malnutrition in childhood: effects on jejunal mucosal morphology and disaccharidase activities.
Malnutrition
[The effect of malnutrition during milk feeding on the enzyme activity of the initial and final stages of carbohydrate hydrolysis in the small intestine of growing rats]
mannosyl-oligosaccharide glucosidase deficiency
A cross-sectional single-centre study on Pompe disease in 42 German patients: Molecular analysis of the GAA gene, manifestation and genotype-phenotype correlations.
mannosyl-oligosaccharide glucosidase deficiency
Broad spectrum of Pompe disease in patients with the same c.-32-13T->G haplotype.
mannosyl-oligosaccharide glucosidase deficiency
Characterization of the molecular defect in infantile and adult acid alpha-glucosidase deficiency fibroblasts.
Melanoma
Inhibition of experimental metastasis by enzyme inhibitors from microorganisms and plants.
Memory Disorders
Deletion mapping of the Drosophila memory mutant amnesiac.
Mesothelioma
Cytology of diffuse mesothelioma in the thorax of a horse.
Metabolic Diseases
alpha1,4-Glucosidase-albumin polymers: in vitro properties and advantages for enzyme replacement therapy.
Metabolic Syndrome
[Pharmacological treatment of postprandial hyperglycemia in hypertensive patients with type 2 diabetes mellitus]
Microsporidiosis
Mucosal abnormalities in microsporidiosis.
Mucolipidoses
Acid hydrolases in serum from patients with lysosomal disorders.
Mucolipidoses
Electrophoretic analysis of glycoprotein enzymes in the sialidoses and mucolipidoses.
Mucopolysaccharidoses
Common antigenicity for two glycosidases.
Mucopolysaccharidosis I
Common antigenicity for two glycosidases.
Mucopolysaccharidosis I
Lysosomal storage diseases.
Mucopolysaccharidosis IV
Lysosomal storage diseases.
Muscle Weakness
Alpha-glucosidase deficiency and basilar artery aneurysm: report of a sibship.
Muscle Weakness
Effects of respiratory muscle training (RMT) in children with infantile-onset Pompe disease and respiratory muscle weakness.
Muscle Weakness
Genotype-phenotype correlation in adult-onset acid maltase deficiency.
Muscle Weakness
Lentiviral gene therapy of murine hematopoietic stem cells ameliorates the Pompe disease phenotype.
Muscle Weakness
Variable clinical features and genotype-phenotype correlations in 18 patients with late-onset Pompe disease.
Muscular Atrophy, Spinal
Cystic fibrosis newborn screening: a model for neuromuscular disease screening?
Muscular Diseases
Abnormal mannose-6-phosphate receptor trafficking impairs recombinant alpha-glucosidase uptake in Pompe disease fibroblasts.
Muscular Diseases
Acid maltase deficiency and related myopathies.
Muscular Diseases
Adult maltase acid deficiency myopathy: treatment with long-term home mechanical ventilation.
Muscular Diseases
An individually, modified approach to desensitize infants and young children with Pompe disease, and significant reactions to alglucosidase alfa infusions.
Muscular Diseases
Clinical consequences of reduced dosing schedule during treatment of a patient with Pompe's disease.
Muscular Diseases
Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients.
Muscular Diseases
Effect of enzyme replacement therapy (ERT) added to Home Mechanical Ventilation (HMV) in Adult Pompe disease.
Muscular Diseases
Effects of non-contractile inclusions on mechanical performance of skeletal muscle.
Muscular Diseases
Improvement of dysphagia in a child affected by Pompe disease treated with enzyme replacement therapy.
Muscular Diseases
New insights into therapeutic options for Pompe disease.
Muscular Diseases
Pharmacological Enhancement of Mutated alpha-Glucosidase Activity in Fibroblasts from Patients with Pompe Disease.
Muscular Diseases
Reduced muscle alpha-glucosidase (acid-maltase) activity in hypothyroid myopathy.
Muscular Diseases
Screening for late-onset Pompe disease in western Denmark.
Muscular Diseases
Selective vacuolar myopathy with atrophy of type II fibers. Occurrence in a childhood case of acid maltase deficiency.
Muscular Diseases
Sleep-related obstructive and nonobstructive apneas and neurologic disorders.
Muscular Diseases
The spectrum of myotonic and myopathic disorders in a pediatric electromyography laboratory over 12 years.
Muscular Diseases
Vacuolar myopathy with type 2 A fiber atrophy and type 2 B fiber deficiency. A case of childhood form acid alpha-1,4-glucosidase deficiency.
Muscular Dystrophy, Duchenne
Cystic fibrosis newborn screening: a model for neuromuscular disease screening?
Myalgia
A case of adult Pompe disease presenting with severe fatigue and selective involvement of type 1 muscle fibers.
Myocardial Infarction
Combination of miglitol, an anti-diabetic drug, and nicorandil markedly reduces myocardial infarct size through opening the mitochondrial K(ATP) channels in rabbits.
Myocardial Infarction
Combination of N-methyl-1-deoxynojirimycin and ischemic preconditioning markedly reduces the size of myocardial infarcts in rabbits.
Myocardial Infarction
Does Treatment of Impaired Glucose Tolerance Improve Cardiovascular Outcomes in Patients with Previous Myocardial Infarction?
Myocardial Infarction
Influence of isoproterenol-induced myocardial infarction on certain glycohydrolases and cathepsins in rats.
Myocardial Infarction
Plasma BNP Levels and Diuretics Use as Predictors of Cardiovascular Events in Patients with Myocardial Infarction and Impaired Glucose Tolerance.
Myocardial Infarction
Serum beta-N-acetylglucosaminidase, beta-D-glucosidase, alpha-D-glucosidase, beta-D-fucosidase, alpha-L-fucosidase and beta-D-galactosidase levels in acute viral hepatitis, pancreatitis, myocardial infarction and breast cancer.
Myotonia Congenita
The spectrum of myotonic and myopathic disorders in a pediatric electromyography laboratory over 12 years.
Myotonic Disorders
The spectrum of myotonic and myopathic disorders in a pediatric electromyography laboratory over 12 years.
Myotonic Dystrophy
Sleep-related obstructive and nonobstructive apneas and neurologic disorders.
Neoplasm Metastasis
Inhibition of experimental metastasis by an alpha-glucosidase inhibitor, 1,6-epi-cyclophellitol.
Neoplasm Metastasis
Inhibition of experimental metastasis by enzyme inhibitors from microorganisms and plants.
Neoplasms
A new 26-norlanostane from Phlogacanthus turgidus growing in Vietnam.
Neoplasms
Activity of alpha-1,4-glucosidase in serum from patients with malignant tumor.
Neoplasms
Activity of glycogen depolymerizing enzymes in extracts from brain tumor tissue (anaplastic astrocytoma and glioblastoma multiforme).
Neoplasms
Alpha-glucosidase inhibitor use is associated with decreased colorectal neoplasia risk in patients with type 2 diabetes mellitus receiving colonoscopy: a retrospective study.
Neoplasms
Alpha-glucosidase inhibitors and risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis.
Neoplasms
Antioxidant, cytotoxic and alpha-glucosidase inhibition activities from the Mexican berry "Anacahuita" (Cordia boissieri).
Neoplasms
Changes in the activities of jejunal glucosidases in experimental intestinal tumorigenesis induced by 1,2 dimethylhydrazine in rats fed different diets.
Neoplasms
Cytological and biochemical methods for the characterization of in vitro cultured cells.
Neoplasms
Diabetes drugs and the incidence of solid cancers: a survey of the current evidence.
Neoplasms
Differential proteome analysis of replicative senescence in rat embryo fibroblasts.
Neoplasms
Effect of incretin-based therapies on cancers of digestive system among 101 595 patients with type 2 diabetes mellitus: a systematic review and network meta-analysis combining 84 trials with a median duration of 30 weeks.
Neoplasms
Expression and different polarity of aminopeptidase N in normal human colonic mucosa and colonic tumors.
Neoplasms
Flow cytometric technique for determination of prostasomal quantity, size and expression of CD10, CD13, CD26 and CD59 in human seminal plasma.
Neoplasms
Inhibition of experimental metastasis by an alpha-glucosidase inhibitor, 1,6-epi-cyclophellitol.
Neoplasms
Pancreatic secretory abnormalities precede appearance of tumors of the pancreas in hamsters treated with bis-(2-oxopropyl)-N-nitrosamine.
Neoplasms
Pharmacokinetic studies on 1-(2-chloroethyl)-3-isobutyl-3-(beta-maltosyl)-1-nitrosourea (TA-077). II. Hydrolysis by tissue homogenates and drug uptake by tumor cells in vitro.
Neoplasms
Secretagogue response of azaserine-induced rat pancreatic acinar tumors in vivo.
Neoplasms
Secretory, enzymatic, and morphological characterization of rat pancreatic endocrine tumours induced by streptozotocin and nicotinamide.
Neoplasms
Structural development of synthetic retinoids and thalidomide-related molecules.
Neoplasms
Sucrase-isomaltase expression and enterocytic ultrastructure of human colorectal tumors.
Neoplasms
The alpha-glucosidase inhibitor miglitol suppresses postprandial hyperglycaemia and interleukin-1beta and tumour necrosis factor-alpha gene expression in rat peripheral leucocytes induced by intermittent sucrose loading.
Nephrosis, Lipoid
Fulminant pneumatosis intestinalis in a patient with diabetes mellitus and minimal change nephrotic syndrome.
Nephrotic Syndrome
Fulminant pneumatosis intestinalis in a patient with diabetes mellitus and minimal change nephrotic syndrome.
Nephrotic Syndrome
Nephrotic syndrome complicating alpha-glucosidase replacement therapy for Pompe disease.
Neuromuscular Diseases
Diagnosis of Pompe disease: muscle biopsy vs blood-based assays.
Non-alcoholic Fatty Liver Disease
alpha-Glucosidase inhibitor acarbose and sequestome 1/A170/p62 deficient mice: A promising therapy and unique model for non-alcoholic fatty liver disease.
Non-alcoholic Fatty Liver Disease
Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease.
Obesity
alpha-Glucosidase inhibition in obesity.
Obesity
Alpha-glucosidase inhibitors 2012 - cardiovascular considerations and trial evaluation.
Obesity
Inhibitory effects of estrogens on digestive enzymes, insulin deficiency, and pancreas toxicity in diabetic rats.
Obesity
Macrophage foam cell formation is augmented in serum from patients with diabetic angiopathy.
Obesity
Polyhydroxylated alkaloids isolated from mulberry trees (Morusalba L.) and silkworms (Bombyx mori L.).
Obesity
Punica granatum flower extract, a potent alpha-glucosidase inhibitor, improves postprandial hyperglycemia in Zucker diabetic fatty rats.
Obesity
The alpha-glucosidase inhibitor acarbose prevents obesity and simple steatosis in sequestosome 1/A170/p62 deficient mice.
Obesity
The alpha-glucosidase inhibitor miglitol affects bile acid metabolism and ameliorates obesity and insulin resistance in diabetic mice.
Obesity
The alpha-glucosidase inhibitor miglitol increases hepatic CYP7A1 activity in association with altered short-chain fatty acid production in the gut of obese diabetic mice.
Obesity
[Drug clinics. How I treat various metabolic diseases treated by a drug intervention that targets the intestine]
Obesity
[The effect of an alpha-glucosidase inhibitor on fatty liver in obesity]
Obesity, Abdominal
[Pharmacological treatment of postprandial hyperglycemia in hypertensive patients with type 2 diabetes mellitus]
oligo-1,6-glucosidase deficiency
Disaccharidase activity in male and female C57BL/6 mice infected with Giardia muris.
oligo-1,6-glucosidase deficiency
Prevalence of Disaccharidase Deficiency in Adults With Unexplained Gastrointestinal Symptoms.
Oligospermia
New discriminatory level for glucosidase activity to diagnose epididymal obstruction or dysfunction.
Oligospermia
[The value of the level of alpha-1,4-glucosidase and seminal l-carnitine in patients with oligoasthenospermia]
Overweight
Clinical, endocrine, and metabolic effects of acarbose, a alpha-glucosidase inhibitor, in overweight and nonoverweight patients with polycystic ovarian syndrome.
Overweight
Daily consumption of Reliv Glucaffect for 8 weeks significantly lowered blood glucose and body weight in 50 subjects.
Overweight
Effects of the treatment with acarbose in elderly overweight type 2 diabetic patients in poor glycemic control with oral hypoglycemic agents or insulin.
Overweight
The effects of the alpha-glucosidase inhibitor BAY g 5421 (Acarbose) on meal-stimulated elevations of circulating glucose, insulin, and triglyceride levels in man.
Pancreatic Diseases
Renal factors in serum trypsinogen 1 metabolism and excretion in chronic pancreatic disease.
Pancreatic Diseases
Renal handling of amylase and immunoreactive trypsin in pancreatic cancer and chronic pancreatitis.
Pancreatic Neoplasms
Measurement of alpha-glucosidase activity in serum from patients with cystic fibrosis or pancreatitis.
Pancreatic Neoplasms
Molecular size distribution of immunoreactive trypsin and renal tubular dysfunction: role in trypsin plasma-urine transfer.
Pancreatic Neoplasms
Renal factors in serum trypsinogen 1 metabolism and excretion in chronic pancreatic disease.
Pancreatic Neoplasms
Renal handling of amylase and immunoreactive trypsin in pancreatic cancer and chronic pancreatitis.
Pancreatic Neoplasms
Renal tubular dysfunction in pancreatic cancer and chronic pancreatitis.
Pancreatitis
Measurement of alpha-glucosidase activity in serum from patients with cystic fibrosis or pancreatitis.
Pancreatitis
Serum beta-N-acetylglucosaminidase, beta-D-glucosidase, alpha-D-glucosidase, beta-D-fucosidase, alpha-L-fucosidase and beta-D-galactosidase levels in acute viral hepatitis, pancreatitis, myocardial infarction and breast cancer.
Pancreatitis, Chronic
Molecular size distribution of immunoreactive trypsin and renal tubular dysfunction: role in trypsin plasma-urine transfer.
Pancreatitis, Chronic
Renal factors in serum trypsinogen 1 metabolism and excretion in chronic pancreatic disease.
Pancreatitis, Chronic
Renal handling of amylase and immunoreactive trypsin in pancreatic cancer and chronic pancreatitis.
Pancreatitis, Chronic
Renal tubular dysfunction in pancreatic cancer and chronic pancreatitis.
Paramyxoviridae Infections
Antiviral effects of glycosylation and glucose trimming inhibitors on human parainfluenza virus type 3.
Pelvic Inflammatory Disease
The influence of inflammation of the human male genital tract on secretion of the seminal markers alpha-glucosidase, glycerophosphocholine, carnitine, fructose and citric acid.
Periodontitis
Glycosidase activities in gingival crevicular fluid in subjects with adult periodontitis or gingivitis.
Peripheral Arterial Disease
Activity of cathepsin D and alpha-glucosidase in muscle from patients with peripheral arterial disease.
Plague
On the role of oligosaccharide trimming in the maturation of Sindbis and influenza virus.
Pneumatosis Cystoides Intestinalis
Correction to: Pneumatosis cystoides intestinalis induced by the alpha-glucosidase inhibitor complicated from sigmoid volvulus in a diabetic patient.
Pneumatosis Cystoides Intestinalis
Pneumatosis cystoides intestinalis after alpha-glucosidase inhibitor treatment in a patient with interstitial pneumonitis.
Pneumatosis Cystoides Intestinalis
Pneumatosis cystoides intestinalis after treatment with an alpha-glucosidase inhibitor.
Pneumatosis Cystoides Intestinalis
Pneumatosis cystoides intestinalis following alpha-glucosidase inhibitor treatment: A case report and review of the literature.
Pneumatosis Cystoides Intestinalis
Pneumatosis cystoides intestinalis in neuropsychiatric systemic lupus erythematosus with diabetes mellitus: case report and literature review.
Pneumatosis Cystoides Intestinalis
Pneumatosis cystoides intestinalis induced by the alpha-glucosidase inhibitor complicated from sigmoid volvulus in a diabetic patient.
Pneumatosis Cystoides Intestinalis
Pneumatosis cystoides intestinalis induced by the alpha-glucosidase inhibitor miglitol.
Pneumatosis Cystoides Intestinalis
Pneumatosis cystoides intestinalis of the ascending colon related to acarbose treatment: a case report.
Pneumatosis Cystoides Intestinalis
Regression of pneumatosis cystoides intestinalis after discontinuing of alpha-glucosidase inhibitor administration.
Pneumoperitoneum
A Rare Case of Benign Pneumatosis Intestinalis with Portal Venous Gas and Pneumoperitoneum Induced by Acarbose.
Polycystic Ovary Syndrome
Clinical, endocrine and metabolic effects of acarbose, an alpha-glucosidase inhibitor, in PCOS patients with increased insulin response and normal glucose tolerance.
Polycystic Ovary Syndrome
Clinical, endocrine, and metabolic effects of acarbose, a alpha-glucosidase inhibitor, in overweight and nonoverweight patients with polycystic ovarian syndrome.
Porcine Reproductive and Respiratory Syndrome
The effect of porcine reproductive and respiratory syndrome virus and porcine epidemic diarrhea virus challenge on growing pigs II: Intestinal integrity and function.
Prediabetic State
Assessing the potential for alpha-glucosidase inhibitors in prediabetic states.
Premature Ejaculation
[Semen biochemical markers and their significance in the patients with premature ejaculation]
Prostatic Neoplasms
Potential risk of alpha-glucosidase inhibitor administration in prostate cancer external radiotherapy by exceptional rectal gas production: a case report.
Prostatitis
Evaluation of seminal plasma parameters in patients with chronic prostatitis or leukocytospermia.
Prostatitis
Inflammatory-associated obstructions of the male reproductive tract.
Prostatitis
The influence of inflammation of the human male genital tract on secretion of the seminal markers alpha-glucosidase, glycerophosphocholine, carnitine, fructose and citric acid.
Protein Deficiency
[Effect of protein deficiency in the female rat diet during pregnancy and lactation on the activity of the membrane and soluble forms of digestive enzymes in the offspring small intestine]
Protein-Energy Malnutrition
Effect of pre- & post-weaning protein energy malnutrition on intestinal sucrase & maltase in rats.
Protein-Energy Malnutrition
Moderate and severe protein energy malnutrition in childhood: effects on jejunal mucosal morphology and disaccharidase activities.
Proteinuria
[Diagnostic value of determining neutral alpha-glucosidase and N-acetyl-beta-D-hexosaminidase activity in the urine in kidney pathology]
Proteinuria
[Modification of total and fractioned proteinuria and lysozyme, urine alpha-glucosidase and beta 2-microglobulin in a team of semiprofessional soccer players in 3 phases of the championship]
Psoriasis
Association between ?-glucosidase inhibitor use and psoriatic disease risk in patients with type 2 diabetes mellitus: A population-based cohort study.
Pyelonephritis
New sensitive markers for the detection of experimental ascending pyelonephritis.
Pyelonephritis
[Neutral alpha glucosidase in human urine as a marker of kidney impairment]
Renal Insufficiency
[Alpha-glucosidase and alanine-amino-peptidase in the early diagnosis of renal failure in obstructive jaundice]
Renal Insufficiency, Chronic
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2016 EXECUTIVE SUMMARY.
Renal Insufficiency, Chronic
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY.
Renal Insufficiency, Chronic
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY.
Renal Insufficiency, Chronic
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY.
Renal Insufficiency, Chronic
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2020 EXECUTIVE SUMMARY.
Renal Insufficiency, Chronic
Digestive-absorptive function of the intestinal brush border in uremia.
Respiratory Insufficiency
Lentiviral gene therapy of murine hematopoietic stem cells ameliorates the Pompe disease phenotype.
Respiratory Insufficiency
Phase I/II trial of adeno-associated virus-mediated alpha-glucosidase gene therapy to the diaphragm for chronic respiratory failure in Pompe disease: initial safety and ventilatory outcomes.
Rotavirus Infections
Differential tropism of EB rotavirus (serotype 3) to small intestine of homologous murine model.
Sleep Apnea, Obstructive
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2016 EXECUTIVE SUMMARY.
Sleep Apnea, Obstructive
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY.
Sleep Apnea, Obstructive
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY.
Sleep Apnea, Obstructive
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY.
Sleep Apnea, Obstructive
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2020 EXECUTIVE SUMMARY.
Starvation
Adaptive changes of intestinal enzymes to nutritional intake in the aging rat.
Starvation
Dietary whey proteins and their peptides or amino acids: effects on the jejunal mucosa of starved rats.
Starvation
Effect of starvation on small intestinal enzyme activity in germ-free rats.
Starvation
Relationship between the changes in gastrin levels and intestinal properties in the starved rat.
Starvation
[The influence of protein starvation on hydrolytic and transport characteristics of the rat small intestine in chronic experiments]
Stomach Neoplasms
Diabetes and risk of subsequent gastric cancer: a population-based cohort study in Taiwan.
sucrose alpha-glucosidase deficiency
The Role of Disaccharidase Deficiencies in Functional Abdominal Pain Disorders-A Narrative Review.
Uremia
Activities of intestinal enzymes in experimental chronic renal insufficiency.
Urinary Tract Infections
Diagnostic potential of urinary enzymes and beta 2-microglobulin in acute urinary tract infection.
Vaccinia
Recombinant HIV envelope expressed in an alpha-glucosidase I-deficient CHO cell line and its parental cell line in the presence of 1-deoxynojirimycin is functional.
Varicocele
Abnormal expression of acid glycosidases in seminal plasma and spermatozoa from infertile men with varicocele.
Varicocele
alpha-1,4-Glucosidase activity in infertile oligoasthenozoospermic men with and without varicocele.
Varicocele
Coiled sperm from infertile patients: characteristics, associated factors and biological implication.
Varicocele
Neutral alpha-1,4-glucosidase in human seminal plasma: molecular forms in varicocele and after vasectomy.
Varicocele
Origin of maltase and variations in infertile men.
Varicocele
[Effects of experimental varicocele on the apoptosis of epididymis epithelium and synthesizing function of the epididymis in rats]
Vascular Diseases
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY.
Vascular Diseases
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY.
Ventricular Dysfunction, Left
N-methyl-1-deoxynojirimycin (MOR-14), an alpha-glucosidase inhibitor, markedly improves postischemic left ventricular dysfunction.
Virus Diseases
Role of membrane phospholipids and glycolipids in the Vero cell surface receptor for rubella virus.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
3.2.1.20 alpha-glucosidase
more
top
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable). 
